DietNArelated O
cardiovascular B-PHE
disease I-PHE
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Protective B-PHE
immunity I-PHE
, O
Overall O
CVD B-PHE
, O
Others O

-DOCSTART- O


Cyclandelate O
produces O
peripheral B-PHE
vasodilation I-PHE
by O
a O
direct O
effect O
on O
vascular B-PHE
smooth I-PHE
muscle I-PHE
. O

Pharmacological O
action O
may O
be O
due O
to O
calcium-channel O
antagonism O
. O

-DOCSTART- O


Cholestyramine O
binds O
bile B-PHE
in O
the O
gastrointestinal O
tract O
to O
prevent O
its O
reabsorption O
. O

-DOCSTART- O


Yin O
Chen O
Hao O
Tang O
, O
a O
Chinese O
prescription O
, O
inhibits O
both O
herpes B-PHE
simplex I-PHE
virus I-PHE
type-1 I-PHE
and I-PHE
type-2 I-PHE
infections I-PHE
in O
vitro O
. O

-DOCSTART- O


Treatment O
of O
palpitation B-PHE
and O
insomnia B-PHE
, O
convulsion B-PHE
, O
epilepsy B-PHE
, O
nebula B-PHE
, O
skin B-PHE
ulcerations I-PHE
difficult O
to O
heal O
. O

-DOCSTART- O


Used O
in O
the O
treatment O
of O
Kaposi's B-PHE
sarcoma I-PHE
and O
cancer B-PHE
of O
the O
lung O
, O
ovarian O
, O
and O
breast O
. O

Abraxane O
is O
specfically O
indicated O
for O
the O
treatment O
of O
metastatic B-PHE
breast I-PHE
cancer I-PHE
and O
locally O
advanced B-PHE
or I-PHE
metastatic I-PHE
non-small I-PHE
cell I-PHE
lung I-PHE
cancer I-PHE
. O

-DOCSTART- O


Acute B-PHE
Lymphoblastic I-PHE
Leukemia I-PHE

-DOCSTART- O


Carcinoma B-PHE
of I-PHE
mammary I-PHE
glands I-PHE
, O
nasopharyngeal B-PHE
carcinoma I-PHE
, O
carcinoma B-PHE
of I-PHE
salivary I-PHE
gland I-PHE
, O
scrofula B-PHE
, O
swelling B-PHE
of I-PHE
skin I-PHE
, O
pain B-PHE
wind I-PHE
. O

-DOCSTART- O


To O
cause O
diuresis B-PHE
, O
to O
invigorate O
the O
spleen B-PHE
function I-PHE
, O
and O
to O
calm O
the O
mind B-PHE
. O

-DOCSTART- O


clear O
heat B-PHE
and O
calm O
the O
fetus O

-DOCSTART- O


Damp-heat B-PHE
dysentery I-PHE
, O
enteritis B-PHE
and O
diarrhea B-PHE
. O

-DOCSTART- O


dry B-PHE
cough I-PHE
due O
to O
lung-heat B-PHE

-DOCSTART- O


For O
clearing O
weakness B-PHE
and O
heat B-PHE

-DOCSTART- O


Exenatide O
is O
a O
functional O
analog O
of O
the O
human O
incretin O
Glucagon-Like O
Peptide-1 O
( O
GLP-1 O
) O
. O

Incretins B-PHE
enhance O
glucose-dependent B-PHE
insulin I-PHE
secretion I-PHE
and O
exhibit O
other O
antihyperglycemic B-PHE
actions I-PHE
following O
their O
release O
into O
the O
circulation O
from O
the O
gut O
. O

The O
GLP-1 B-PHE
system I-PHE
increases O
insulin B-PHE
secretion I-PHE
only O
in O
the O
presence O
of O
elevated O
plasma O
glucose O
levels O
, O
avoiding O
inappropriately O
high B-PHE
insulin I-PHE
levels I-PHE
during O
fasting O
. O

The O
drug O
also O
moderates O
peak O
serum B-PHE
glucagon I-PHE
levels I-PHE
during O
hyperglycemic O
periods O
following O
meals O
, O
but O
does O
not O
interfere O
with O
glucagon B-PHE
release I-PHE
in O
response O
to O
hypoglycemia O
. O

Secondary O
effects O
of O
drug O
administration O
reduces O
the O
rate B-PHE
of I-PHE
gastric I-PHE
emptying I-PHE
and O
decreases O
food B-PHE
intake I-PHE
, O
mitigating O
the O
potential O
severity B-PHE
of I-PHE
hyperglycemic I-PHE
events I-PHE
after O
meals O
. O

-DOCSTART- O


Intelligence O
, O
Mental B-PHE
state I-PHE
and O
performance O

-DOCSTART- O


Investigated O
for O
use/treatment O
in O
parkinson's B-PHE
disease I-PHE
. O

-DOCSTART- O


Good O
evidence O
exists O
that O
this O
drug O
bind O
strongly O
, O
but O
reversibly O
, O
to O
DNA B-PHE
, O
interfering O
with O
synthesis B-PHE
of I-PHE
RNA I-PHE
( O
prevention O
of O
RNA B-PHE
polymerase I-PHE
elongation I-PHE
) O
and O
, O
consequently O
, O
with O
protein B-PHE
synthesis I-PHE
. O

-DOCSTART- O


Wind-cold-damp B-PHE
impediment O
, O
paralysis B-PHE
, O
painful O
wound B-PHE
from O
knocks O
and O
falls O
, O
tetanus O
. O

-DOCSTART- O


Halobetasol O
propionate O
is O
thought O
to O
act O
by O
the O
induction O
of O
phospholipase O
A2 O
inhibitory O
proteins O
, O
collectively O
called O
lipocortins O
. O

It O
is O
postulated O
that O
these O
proteins O
control O
the O
biosynthesis B-PHE
of O
potent O
mediators O
of O
inflammation O
such O
as O
prostaglandins B-PHE
and O
leukotrienes B-PHE
by O
inhibiting O
the O
release O
of O
their O
common O
precursor O
arachidonic B-PHE
acid I-PHE
. O

Arachidonic O
acid O
is O
released O
from O
membrane O
phospholipids O
by O
phospholipase O
A2 O
. O

The O
initial O
interaction O
, O
however O
, O
is O
due O
to O
the O
drug O
binding O
to O
the O
cytosolic O
glucocorticoid O
receptor O
. O

After O
binding O
the O
receptor O
the O
newly O
formed O
receptor-ligand O
complex O
translocates O
itself O
into O
the O
cell O
nucleus O
, O
where O
it O
binds O
to O
many O
glucocorticoid O
response O
elements O
( O
GRE O
) O
in O
the O
promoter O
region O
of O
the O
target O
genes O
. O

The O
DNA O
bound O
receptor O
then O
interacts O
with O
basic O
transcription B-PHE
factors I-PHE
, O
causing O
the O
increase O
in O
expression B-PHE
of I-PHE
specific I-PHE
target I-PHE
genes I-PHE
. O

-DOCSTART- O


fetal B-PHE
irritability I-PHE
; O
threatened B-PHE
abortion I-PHE
; O
excessive O
fetal O
movements O
continuous O
moving O
of O
the O
fetus O
causing O
pain B-PHE
in I-PHE
the I-PHE
lower I-PHE
abdomen I-PHE
. O

-DOCSTART- O


Cisplatin O
complexes O
react O
in O
vivo O
, O
binding O
to O
and O
causing O
crosslinking O
of O
DNA B-PHE
which O
ultimately O
triggers O
apoptosis B-PHE
( O
programmed O
cell B-PHE
death I-PHE
) O
. O

Gemcitabine O
is O
converted O
intracellularly O
to O
the O
active O
metabolites O
difluorodeoxycytidine O
di- O
and O
triphosphate O
( O
dFdCDP O
, O
dFdCTP O
) O
. O

dFdCDP O
inhibits O
ribonucleotide B-PHE
reductase I-PHE
, O
thereby O
decreasing O
the O
deoxynucleotide O
pool O
available O
for O
DNA B-PHE
synthesis I-PHE
; O
dFdCTP O
is O
incorporated O
into O
DNA B-PHE
, O
resulting O
in O
DNA B-PHE
strand I-PHE
termination I-PHE
and O
apoptosis B-PHE
. O

-DOCSTART- O


For O
breaking O
blood B-PHE
and O
desolving O
stasis B-PHE

-DOCSTART- O


A O
high O
performance O
liquid O
chromatography-hydride O
generation-atomic O
fluorescence O
spectrometry O
( O
HPLC-HG-AFS O
) O
method O
was O
developed O
for O
the O
simultaneous O
determination O
of O
four O
arsenic O
species O
( O
As(III) O
) O
, O
dimethylarsinic O
acid O
( O
DMA O
) O
, O
monomethylarsonic O
acid O
( O
MMA O
) O
and O
arsenate O
As(V) O
in O
dog O
plasma O
. O

Good O
separation O
of O
the O
four O
arsenic O
species O
was O
achieved O
within O
15min O
on O
an O
anion-exchange O
column O
with O
isocratic O
elution O
using O
15mmol/L O
KH(2)PO(4 O
) O
( O
pH O
5.9 O
) O
as O
eluent O
at O
a O
flow O
rate O
of O
1.0mL/min O
. O

The O
assay O
was O
linear O
over O
the O
range O
of O
1.25-200 O
, O
1.56-200 O
, O
1.34-172 O
, O
and O
2.50-200ng/mL O
with O
the O
detection O
limits O
of O
0.8 O
, O
1 O
, O
0.86 O
and O
2.00ng/mL O
for O
As O
( O
III O
) O
, O
DMA O
, O
MMA O
and O
As O
( O
V O
) O
, O
respectively O
. O

The O
method O
was O
validated O
for O
selectivity O
, O
precision O
, O
accuracy O
and O
recovery O
and O
then O
applied O
to O
a O
comparative O
pharmacokinetic O
study O
of O
the O
arsenic O
species O
in O
beagle O
dogs O
after O
a O
single O
oral O
administration O
of O
Realgar O
( O
24.32mg/kg O
, O
equivalent O
to O
11.31mgAs/kg O
) O
alone O
or O
Niu O
Huang O
Jie O
Du O
Pian O
(a O
patent O
traditional O
Chinese O
medicine O
( O
TCM O
) O
, O
380mg/kg O
, O
equivalent O
to O
28.45mgAs/kg O
) O
, O
respectively O
. O

DMA O
was O
found O
to O
be O
the O
predominant O
species O
in O
the O
dog O
plasma O
after O
dosing O
, O
with O
As(V O
) O
appeared O
as O
the O
quickly O
eliminating O
one O
. O

No O
traces O
of O
MMA O
and O
As(III O
) O
were O
detected O
at O
any O
sampling O
time O
points O
. O

The O
main O
pharmacokinetic O
parameters O
found O
for O
DMA O
p.o O
. O
administration O
of O
Realgar O
and O
Niu O
Huang O
Jie O
Du O
Pian O
were O
as O
follows O
: O
C(max O
) O
( O
14.7 O
4.2 O
) O
and O
( O
57 O
32.0)ng/mL O
, O
T(max O
) O
( O
2.4 O
0.5 O
) O
and O
( O
2.5 O
0.5)h O
, O
AUC(0-36 O
) O
( O
151.1 O
12.9 O
) O
and O
( O
635.9 O
418.2)ngh/mL O
, O
AUC(0- O
) O
( O
206 O
44.5 O
) O
and O
( O
687.2 O
425.1)ngh/mL O
, O
t(1/2 O
) O
( O
16.2 O
7.9 O
) O
and O
( O
9.4 O
2.2)h O
, O
respectively O
. O

The O
influence O
of O
compounding O
in O
Niu O
Huang O
Jie O
Du O
Pian O
on O
the O
pharmacokinetics O
of O
arsenics O
was O
shown O
with O
increased O
transformation O
of O
DMA O
and O
its O
faster O
elimination O
rate O
. O

-DOCSTART- O


To O
remove O
heat B-PHE
and O
damp B-PHE
, O
to O
counteract O
toxicity B-PHE
, O
and O
to O
cause O
subsidence B-PHE
of I-PHE
swelling I-PHE
. O

-DOCSTART- O


Treatment O
of O
headache B-PHE
and O
dizziness B-PHE
, O
costal B-PHE
and I-PHE
abdomina I-PHE
pain I-PHE
, O
spasmodic B-PHE
pain I-PHE
of O
the O
limbs O
, O
anemia B-PHE
, O
menstrual B-PHE
disorders I-PHE
, O
spontaneous O
sweating B-PHE
and O
night B-PHE
sweating I-PHE
. O

-DOCSTART- O


Mounting O
qi O
( O
hernia B-PHE
) O
, O
profuse B-PHE
menstruation I-PHE
. O

-DOCSTART- O


arrest O
cough B-PHE
and O
relieve O
asthms B-PHE

-DOCSTART- O


acute O
infantile B-PHE
convulsion I-PHE

-DOCSTART- O


cough B-PHE
due O
to O
wind-cold B-PHE

-DOCSTART- O


Cold B-PHE
pain I-PHE
in O
stomach O
duct O
and O
abdomen O
, O
indigestion B-PHE
, O
vomiting B-PHE
nausea B-PHE
, O
diarrhea B-PHE
, O
cold B-PHE
mounting O
, O
dysmenorrhea B-PHE
, O
urethral B-PHE
stone I-PHE
, O
swelling B-PHE
pain I-PHE
of O
sore O
and O
boil O
. O

-DOCSTART- O


To O
reduce O
swelling B-PHE
and O
promote O
healing B-PHE
. O

-DOCSTART- O


Acute B-PHE
Viral I-PHE
Bronchiolitis I-PHE

-DOCSTART- O


AIDS B-PHE
With O
Tuberculosis B-PHE

-DOCSTART- O


Red B-PHE
eyes I-PHE
with O
gall O
, O
pulmonary O
welling O
abscess B-PHE
, O
diarrhea B-PHE
, O
dysentery B-PHE
, O
leukorrhea B-PHE
, O
postpartum O
blood B-PHE
stasis I-PHE
abdominal B-PHE
pain I-PHE
, O
indigestion B-PHE
, O
nephritis B-PHE
with O
edema B-PHE
, O
cirrhosis B-PHE
with O
ascites B-PHE
, O
swelling B-PHE
toxin O
of O
welling B-PHE
abscess I-PHE
and O
sore B-PHE
. O

-DOCSTART- O


promote O
the O
intestine B-PHE

-DOCSTART- O


To O
clear O
heat B-PHE
and O
cool O
blood B-PHE
; O

To O
benefit O
qi O
and O
contain O
blood B-PHE
; O
To O
revitalize O
blood B-PHE
and O
desolve O
stagnation B-PHE

-DOCSTART- O


For O
treatment O
and O
management O
of O
epilepsy B-PHE
and O
seizures B-PHE
associated O
with O
Lennox-Gastaut B-PHE
syndrome I-PHE
, O
a O
difficult-to-treat O
form O
of O
childhood B-PHE
epilepsy I-PHE
. O

-DOCSTART- O


Hemophilia B-PHE
A I-PHE

-DOCSTART- O


sore B-PHE

-DOCSTART- O


general O
swelling B-PHE
and O
small B-PHE
amount I-PHE
urine I-PHE

-DOCSTART- O


1 O
Since O
the O
prescription O
possesses O
a O
hemostatic O
action O
, O
it O
is O
also O
indicated O
for O
incised B-PHE
wounds I-PHE
with O
hemorrhage B-PHE
( O
topical O
use O
) O
. O

2 O
Applicable O
to O
cases O
of O
angina B-PHE
pectoris I-PHE
which O
are O
attributive O
to O
retention O
of O
blood B-PHE
stasis I-PHE
. O

3 O
Also O
applicable O
orally O
or O
topi O

-DOCSTART- O


Hypertension B-PHE
, O
kidney B-PHE
vacuity I-PHE
lumbago I-PHE
, O
weakness B-PHE
in O
sinews O
and O
bones O
, O
stirring O
fetus O
in O
pregnancy O
. O

-DOCSTART- O


ADHD B-PHE

-DOCSTART- O


Adult B-PHE
Acute I-PHE
Megakaryoblastic I-PHE
Leukemia I-PHE

-DOCSTART- O


excessive B-PHE
thought I-PHE
; O
anxiety O

-DOCSTART- O


To O
calm O
the O
liver O
and O
suppress O
the O
asthenic B-PHE
yang O
, O
to O
promote O
the O
restoration O
of O
consciousness O
, O
decrease O
blood B-PHE
pressure I-PHE
. O

-DOCSTART- O


Urinary B-PHE
systems I-PHE
, O
Urinary B-PHE
system I-PHE
health I-PHE
, O
Liver B-PHE
health I-PHE
, O
Liver B-PHE

-DOCSTART- O


This O
is O
a O
syndrome O
with O
chronic B-PHE
coughing I-PHE
and O
inflammation B-PHE
in O
urination O
. O

-DOCSTART- O


Intelligence B-PHE
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Others O
, O
Protective O
immunity B-PHE
, O
Mental B-PHE
state I-PHE
and I-PHE
performance I-PHE

-DOCSTART- O


a O
symptom O
of O
having O
muscular B-PHE
flaccidity I-PHE
due O
to O
deficiency O
of O
Gi O
, O
and O
insufficiency B-PHE
of I-PHE
nourishment I-PHE
in O
organs O
due O
to O
deficiency B-PHE
of I-PHE
blood I-PHE

-DOCSTART- O


Decanoyl O
acetaldehyde O
is O
bacteriostatic O
and O
fungistatic O
. O

Its O
decoction O
retards O
the O
progress O
of O
tuberculosis B-PHE
experimentally O
. O

Synthetic O
product O
( O
compound O
of O
decanoyl O
acetaldehyde O
and O
NaHSO3 O
) O
promotes O
white B-PHE
cell I-PHE
phagocytosis I-PHE
. O

Anti-inflammation B-PHE
. O

Quercitrin O
, O
an O
active O
component O
, O
is O
a O
strong O
diuretic O
, O
and O
exerts O
such O
effect O
in O
a O
1 O
: O
10 O
, O
0 O
solution O
. O

-DOCSTART- O


To O
move O
qi O
, O
precipitate O
qi O
, O
relieve O
pain B-PHE
, O
disperse O
distention O
, O
free O
milk O
. O

-DOCSTART- O


Based O
on O
the O
behavior O
of O
protons O
when O
placed O
in O
a O
strong O
magnetic O
field O
, O
which O
is O
interpreted O
and O
transformed O
into O
images O
by O
magnetic O
resonance O
( O
MR O
) O
instruments O
. O

Paramagnetic O
agents O
have O
unpaired O
electrons O
that O
generate O
a O
magnetic O
field O
about O
700 O
times O
larger O
than O
the O
proton's O
field O
, O
thus O
disturbing O
the O
proton's O
local O
magnetic O
field O
. O

When O
the O
local O
magnetic O
field O
around O
a O
proton O
is O
disturbed O
, O
its O
relaxation O
process O
is O
altered O
. O

MR O
images O
are O
based O
on O
proton O
density O
and O
proton O
relaxation O
dynamics O
. O

MR O
instruments O
can O
record O
2 O
different O
relaxation O
processes O
, O
the O
T1 O
( O
spin-lattice O
or O
longitudinal O
relaxation O
time O
) O
and O
the O
T2 O
( O
spin-spin O
or O
transverse O
relaxation O
time O
) O
. O

In O
magnetic O
resonance O
imaging O
( O
MRI O
) O
, O
visualization O
of O
normal O
and O
pathological O
brain O
tissue O
depends O
in O
part O
on O
variations O
in O
the O
radiofrequency O
signal O
intensity O
that O
occur O
with O
changes O
in O
proton O
density O
, O
alteration O
of O
the O
T1 O
, O
and O
variation O
in O
the O
T2 O
. O

When O
placed O
in O
a O
magnetic O
field O
, O
gadodiamide O
shortens O
both O
the O
T1 O
and O
the O
T2 O
relaxation O
times O
in O
tissues O
where O
it O
accumulates O
. O

At O
clinical O
doses O
, O
gadodiamide O
primarily O
affects O
the O
T1 O
relaxation O
time O
, O
thus O
producing O
an O
increase O
in O
signal O
intensity O
. O

Gadodiamide O
does O
not O
cross O
the O
intact O
blood-brain B-PHE
barrier I-PHE
; O
therefore O
, O
it O
does O
not O
accumulate O
in O
normal O
brain O
tissue O
or O
in O
central B-PHE
nervous I-PHE
system I-PHE
( O
CNS B-PHE
) O
lesions B-PHE
that O
have O
not O
caused O
an O
abnormal O
blood-brain B-PHE
barrier I-PHE
( O
e.g O
. O
, O
cysts B-PHE
, O
mature O
post-operative O
scars O
) O
. O

Abnormal B-PHE
vascularity I-PHE
or O
disruption B-PHE
of I-PHE
the I-PHE
blood-brain I-PHE
barrier I-PHE
allows O
accumulation O
of O
gadodiamide B-PHE
in I-PHE
lesions I-PHE
such O
as O
neoplasms B-PHE
, O
abscesses B-PHE
, O
and O
subacute B-PHE
infarcts I-PHE
. O

-DOCSTART- O


vomiting B-PHE
and O
regurgitation B-PHE

-DOCSTART- O


Inhibited O
urination B-PHE
, O
dribbling O
pain B-PHE
of O
urination O
, O
edema B-PHE
, O
bloody B-PHE
urine I-PHE
, O
damp-heat B-PHE
dysentery I-PHE
, O
asthma B-PHE
, O
sore B-PHE
swollen I-PHE
throat I-PHE
, O
toxin B-PHE
swelling I-PHE
of O
sores O
, O
wind-damp B-PHE
pain I-PHE
, O
menstrual B-PHE
disorder I-PHE
, O
knocks B-PHE
and O
falls B-PHE
, O
bleeding B-PHE
knife O
wound O
. O

-DOCSTART- O


This O
is O
a O
syndrome B-PHE
with I-PHE
bloat I-PHE
and I-PHE
fullness I-PHE
in I-PHE
abdominal I-PHE
region I-PHE
. O

-DOCSTART- O


swelling B-PHE
and O
bearing-down B-PHE
pain I-PHE
of O
unilateral O
testis O
; O
unilateral O
swelling B-PHE
of I-PHE
the I-PHE
testis I-PHE

-DOCSTART- O


Boils B-PHE
and O
carbuncles B-PHE
. O

-DOCSTART- O


release O
the O
exterior O
and O
dispel O
wind B-PHE

-DOCSTART- O


Treatment O
of O
weakness B-PHE
of I-PHE
the I-PHE
spleen I-PHE
and I-PHE
the I-PHE
lung I-PHE
manifested O
by O
shortness B-PHE
of I-PHE
breath I-PHE
, O
cough B-PHE
, O
palpitation B-PHE
, O
anorexia B-PHE
, O
loose B-PHE
stools I-PHE
, O
diabetes B-PHE
caused O
by O
internal O
heat B-PHE
. O

-DOCSTART- O


inflammation B-PHE
of O
the O
throat O
; O
sore B-PHE
throat I-PHE
; O
hoarse B-PHE
voice I-PHE
; O
aphonia B-PHE

-DOCSTART- O


Its O
aqueous O
infusion O
inhibits O
the O
growth B-PHE
of I-PHE
skin I-PHE
fungi I-PHE
such O
as O
Trichophyton B-PHE
violaceum I-PHE
. O

-DOCSTART- O


To O
enrich O
the O
blood B-PHE
, O
to O
activate O
blood B-PHE
circulation I-PHE
, O
and O
to O
remove O
obstruction O
of O
the O
channels O
and O
collaterals O
. O

-DOCSTART- O


Chronic B-PHE
Fatigue I-PHE

-DOCSTART- O


Endocrine B-PHE
system I-PHE
, O
insulin B-PHE
sensitivity I-PHE
and O
diabetes B-PHE
risk I-PHE
, O
Body B-PHE
weight I-PHE
regulation I-PHE
, O
Improvement O
of O
blood B-PHE
glucose I-PHE
levels I-PHE
, O
Endocrine B-PHE
& I-PHE
reproductive I-PHE
systems I-PHE

-DOCSTART- O


For O
the O
treatment O
of O
the O
following O
mild-to-moderate B-PHE
infections I-PHE
caused O
by O
susceptible O
strains O
of O
microorganisms O
: O
acute B-PHE
bacterial I-PHE
exacerbations I-PHE
of I-PHE
chronic I-PHE
bronchitis I-PHE
, O
secondary B-PHE
bacterial I-PHE
infection I-PHE
of O
acute B-PHE
bronchitis I-PHE
, O
community B-PHE
- I-PHE
acquired I-PHE
pneumonia I-PHE
, O
pharyngitis B-PHE
/ O
tonsilitis B-PHE
, O
and O
uncomplicated B-PHE
skin I-PHE
and O
skin B-PHE
structure I-PHE
infections I-PHE
. O

-DOCSTART- O


To O
remove O
heat B-PHE
from O
the O
lung O
and O
relieve O
sore B-PHE
throat I-PHE
, O
and O
to O
regulate O
the O
flow O
of O
qi O
of O
the O
liver O
and O
the O
stomach O
. O

-DOCSTART- O


To O
clear O
heat B-PHE
and O
resolve O
toxin B-PHE
, O
disinhibit O
water O
and O
disperse O
edema B-PHE
. O

-DOCSTART- O


To O
clear O
away O
heat B-PHE
and O
toxic B-PHE
materials I-PHE
. O

-DOCSTART- O


post B-PHE
delivery I-PHE
, O
Body B-PHE
weight I-PHE
regulation I-PHE
, O
Woman O
, O
Diet B-PHE
related I-PHE
cardiovascular I-PHE
disease I-PHE
, O
Hypersensitivity B-PHE
, O
motility B-PHE
, O
Others O
, O
Body B-PHE
weight I-PHE
, O
Protective B-PHE
immunity I-PHE
, O
Quality O
of O
life O
, O
Hemostatic B-PHE
function I-PHE
, O
Inflammation B-PHE

-DOCSTART- O


pull O
up O
toxicity B-PHE
and O
regenerate O
flesh B-PHE

-DOCSTART- O


This O
is O
a O
syndrome O
of O
a O
retarded B-PHE
child I-PHE
. O

There O
are O
five O
symptoms O
including O
slow B-PHE
stand I-PHE
, O
delayed O
development O
in O
walking O
, O
retardation O
in O
hair-growing O
, O
delayed B-PHE
development I-PHE
in O
growth O
of O
teeth O
, O
and O
delayed B-PHE
development I-PHE
of O
speech O
in O
an O
infant O
. O

-DOCSTART- O


Pulmonary O
Aspiration O

-DOCSTART- O


nourish O
Eum O
( O
Yin O
) O
and O
reinforce O
blood B-PHE

-DOCSTART- O


stop O
bleeding B-PHE
; O
hemostasis B-PHE

-DOCSTART- O


freckles B-PHE
on O
face O

-DOCSTART- O


Filgrastim O
binds O
to O
the O
G-CSF O
receptor O
and O
stimulates O
the O
production B-PHE
of I-PHE
neutrophils I-PHE
in O
the O
bone O
marrow O
. O

-DOCSTART- O


Tretinoin O
binds O
to O
and O
activates O
retinoic O
acid O
receptors O
( O
RARs O
) O
, O
thereby O
inducing O
changes O
in O
gene B-PHE
expression I-PHE
that O
lead O
to O
cell B-PHE
differentiation I-PHE
, O
decreased B-PHE
cell I-PHE
proliferation I-PHE
, O
and O
inhibition B-PHE
of I-PHE
tumorigenesis I-PHE
. O

-DOCSTART- O


Heart B-PHE
Failure I-PHE
. O

-DOCSTART- O


juvenile O
onset O
smallpox B-PHE
poison O

-DOCSTART- O


Childhood B-PHE
Acute I-PHE
Myeloid I-PHE
Leukemia I-PHE
Without O
Maturation B-PHE

-DOCSTART- O


pain B-PHE
in O
ear O

-DOCSTART- O


Numbness B-PHE
of I-PHE
the I-PHE
extremities I-PHE
, O
aching B-PHE
of O
the O
joints O
and O
menstrual B-PHE
disorders I-PHE
due O
to O
deficiency B-PHE
of I-PHE
blood I-PHE
. O

-DOCSTART- O


abdominal B-PHE
mass I-PHE

-DOCSTART- O


This O
is O
a O
symptom O
with O
fullness B-PHE
and I-PHE
pain I-PHE
in I-PHE
the I-PHE
chest I-PHE
and I-PHE
abdomen I-PHE
. O

-DOCSTART- O


To O
dissipate O
cold B-PHE
and O
relieve O
pain B-PHE
, O
rectify O
qi O
and O
regulate O
center O
. O

-DOCSTART- O


Treatment O
of O
hemoptysis B-PHE
, O
hematemesis B-PHE
, O
epistaxis B-PHE
, O
hematochezia B-PHE
, O
abnormal B-PHE
uterine I-PHE
bleeding I-PHE
, O
traumatic B-PHE
bleeding I-PHE
, O
pricking O
pain B-PHE
in O
the O
chest O
and O
abdomen O
, O
traumatic B-PHE
swelling I-PHE
and O
pain B-PHE
. O

-DOCSTART- O


Coronary O
Artery O
Bypass O
Graft O
Redo O

-DOCSTART- O


deficiency B-PHE
and I-PHE
chills I-PHE
of I-PHE
uterus I-PHE

-DOCSTART- O


frequent B-PHE
vomiting I-PHE

-DOCSTART- O


epigastric O
twisting O
pain B-PHE
. O

-DOCSTART- O


Lopinavir O
inhibits O
the O
HIV B-PHE
viral I-PHE
protease I-PHE
enzyme I-PHE
. O

-DOCSTART- O


Statin O
Therapy O

-DOCSTART- O


TBC3711 O
is O
a O
small O
molecule O
that O
blocks O
the O
action O
of O
endothelin O
, O
a O
potent O
mediator O
of O
blood O
vessel O
constriction O
and O
growth O
of O
smooth O
muscle O
in O
vascular B-PHE
walls I-PHE
. O
It O
is O
a O
next-generation O
endothelin O
A O
antagonist O
which O
possesses O
high O
oral O
bioavailability O
and O
is O
more O
selective O
and O
potent O
than O
THELIN(tm O
) O
( O
sitaxsentan O
sodium O
) O
Encysive's O
oral O
treatment O
for O
pulmonary B-PHE
arterial I-PHE
hypertension I-PHE
. O

TBC3711 O
is O
greater O
than O
100,000-fold O
selective O
in O
the O
targeting O
of O
the O
endothelin O
A O
receptor O
versus O
the O
endothelin O
B O
receptor O
. O

-DOCSTART- O


insulin O
sensitivity O
and O
diabetes B-PHE
risk O
, O
Body B-PHE
weight I-PHE
regulation O
, O
Woman O
, O
Reproductive B-PHE
systems I-PHE
, O
Endocrine B-PHE
& I-PHE
reproductive I-PHE
systems I-PHE
, O
Endocrine B-PHE
system I-PHE
, O
Bone B-PHE
Health I-PHE
and O
Osteoporosis B-PHE
, O
Quality O
of O
life O
, O
Menopausal B-PHE
woman O
, O
Eldery O
, O
Liver B-PHE
health I-PHE
, O
Metabolism B-PHE
, O
Mimmuietabolic O
rate/energy O
expenditure O
, O
Bone B-PHE
metabolism/density B-PHE
, O
Memory O
, O
Liver O
, O
Others O
, O
Mental B-PHE
state I-PHE
and O
performance O
, O
Man O

-DOCSTART- O


swelling B-PHE
of O
the O
foot O
; O
edema B-PHE
of O
foot O

-DOCSTART- O


Obesity B-PHE
and O
Obesity-related B-PHE
Medical O
Conditions O

-DOCSTART- O


frost B-PHE
bite I-PHE
; O
chilblain B-PHE
; O
frostbite B-PHE

-DOCSTART- O


Migraine B-PHE

-DOCSTART- O


Wind-damp B-PHE
impediment O
pain B-PHE
, O
taxation O
damage O
in O
lumbar B-PHE
muscle I-PHE
, O
knocks O
and O
falls O
. O

-DOCSTART- O


Stage O
IV O
Adult B-PHE
T-Cell I-PHE
Leukemia/Lymphoma I-PHE

-DOCSTART- O


For O
the O
treatment O
of O
heparin-induced B-PHE
thrombocytopenia I-PHE

-DOCSTART- O


Protective B-PHE
immunity I-PHE
, O
Urinary B-PHE
systems I-PHE
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Urinary B-PHE
system I-PHE
health I-PHE

-DOCSTART- O


For O
cooling O
blood B-PHE
and O
stopping O
bleeding B-PHE

-DOCSTART- O


Stage O
III O
Adult B-PHE
Lymphoblastic I-PHE
Lymphoma I-PHE

-DOCSTART- O


chest O
and O
hypochondriac O
pain O

-DOCSTART- O


This O
is O
bleeding B-PHE
due O
to O
an O
external B-PHE
wound I-PHE
. O

-DOCSTART- O


glad O
and O
misten B-PHE
complexion I-PHE

-DOCSTART- O


Treatment O
of O
taeniasis B-PHE
, O
ancylostomiasis B-PHE
, O
ascariasis B-PHE
, O
intestinal B-PHE
parasitosis I-PHE
with O
abdominal B-PHE
pain I-PHE
or O
with O
infantile B-PHE
malnutrition I-PHE
. O

-DOCSTART- O


cough B-PHE
due O
to O
lung B-PHE
subcutaneous I-PHE
nodes I-PHE

-DOCSTART- O


For O
desolving O
phlegm B-PHE
, O
stopping O
cougth B-PHE
, O
and O
soothing O
breathing B-PHE

-DOCSTART- O


Roundworm B-PHE

-DOCSTART- O


Liver B-PHE
health I-PHE
, O
Liver B-PHE
, O
Others O

-DOCSTART- O


fever B-PHE

-DOCSTART- O


For O
the O
treatment O
of O
EGFR-expressing O
, O
metastatic B-PHE
colorectal I-PHE
carcinoma I-PHE
that O
is O
refractory O
to O
fluoropyrimidine- O
, O
oxaliplatin- O
, O
and O
irinotecan- O
containing O
chemotherapy O
regimens O
. O

-DOCSTART- O


Rheumatism B-PHE
numbness I-PHE
, O
damp-heat B-PHE
itchy I-PHE
sore I-PHE
, O
clove B-PHE
sore I-PHE
, O
menstruant O
morbidity O
. O

-DOCSTART- O


To O
soothe O
the O
liver B-PHE
and O
regulate O
the O
circulation O
of O
qi O
, O
clear O
away O
heat B-PHE
and O
toxic O
materials O
. O

-DOCSTART- O


new O
and O
old O
cough B-PHE

-DOCSTART- O


To O
supplement O
blood B-PHE
and O
quicken O
blood B-PHE
, O
free O
channels B-PHE
and O
quicken O
network B-PHE
vessels I-PHE
. O

-DOCSTART- O


Untreated O
Adult B-PHE
Acute I-PHE
Lymphoblastic I-PHE
Leukemia I-PHE

-DOCSTART- O


Edema B-PHE
due O
to O
deficiency B-PHE
in I-PHE
the I-PHE
kidney I-PHE
, O
accompanied O
with O
heaviness O
sensation O
in O
the O
loins O
and O
knees O
and O
oliguria O
; O

retention O
of O
body O
fluid O
with O
dyspnea B-PHE
and O
cough B-PHE
. O

-DOCSTART- O


leukorrhea B-PHE
with O
pruritis B-PHE
vulva I-PHE

-DOCSTART- O


Liver O
Transplantation O

-DOCSTART- O


To O
regulate O
menstruation B-PHE
, O
replenish O
blood B-PHE
and O
regulate O
qi O
to O
relieve O
pain B-PHE
. O

-DOCSTART- O


To O
supplement O
blood B-PHE
, O
quicken B-PHE
blood I-PHE
, O
strengthen O
lumbus B-PHE
and O
knees B-PHE
. O

-DOCSTART- O


Treatment O
of O
mass B-PHE
in O
the O
abdomen O
, O
amenorrhea B-PHE
due O
to O
blood B-PHE
stasis I-PHE
, O
abdominal B-PHE
distension I-PHE
and O
pain B-PHE
caused O
by O
retention O
of O
undigested O
food O
. O

-DOCSTART- O


To O
eliminate O
toxic B-PHE
material I-PHE
, O
promote O
pus B-PHE
drainage I-PHE
and O
remove O
blood B-PHE
stasis I-PHE
. O

-DOCSTART- O


Papillary B-PHE
serous I-PHE
endometrial I-PHE
cancer I-PHE

-DOCSTART- O


Chronic B-PHE
Hepatitis I-PHE
B I-PHE
Virus I-PHE
, O
Pediatric O

-DOCSTART- O


1 O
To O
remove O
blood B-PHE
stasis I-PHE
and O
alleviate O
pain B-PHE
. O

For O
stomachache B-PHE
, O
headache B-PHE
, O
toothache B-PHE
, O
trauma B-PHE
and O
rheumatism O
. O

2 O
To O
clear O
heat B-PHE
and O
toxic B-PHE
material I-PHE
. O

For O
sorethroat B-PHE
, O
aphthae B-PHE
, O
carbuncle B-PHE
, O
burn B-PHE
, O
snake B-PHE
bite I-PHE
, O
dysentery B-PHE
and O
diarrhea B-PHE
. O

3 O
To O
relax O
the O
muscles O
. O

As O
a O
muscle O
relaxant O
for O
restoration O
of O
fracture B-PHE
and O
surgical O
operation O
. O

-DOCSTART- O


Chloramphenicol O
reversibly O
binds O
to O
the O
L16 B-PHE
protein I-PHE
of O
the O
50S B-PHE
subunit I-PHE
of I-PHE
bacterial I-PHE
ribosomes I-PHE
, O
thus O
inhibits O
protein B-PHE
synthesis I-PHE
. O

Desoxyribonuclease O
is O
a O
biosynthetic O
form O
of O
human O
DNase B-PHE
I I-PHE
, O
which O
is O
involved O
in O
endonucleolytic O
cleavage O
of O
extracellular B-PHE
DNA I-PHE
to O
5-phosphodinucleotide O
and O
5-phosphooligonucleotide O
end O
products O
. O

Fibrinolysin O
attacks O
and O
inactivates O
fibrin B-PHE
molecules I-PHE
occurring O
in O
undesirable O
exudates O
on O
the O
surface O
of O
the O
human O
body O
and O
on O
human B-PHE
mucosa I-PHE
. O

-DOCSTART- O


pulmonary B-PHE
carbuncle I-PHE
; O
lung B-PHE
abscess I-PHE

-DOCSTART- O


a O
disease O
that O
tendons B-PHE
and O
bones B-PHE
become O
dry O

-DOCSTART- O


vomiting B-PHE

-DOCSTART- O


Yang O
poison B-PHE
; O
extreme O
heat B-PHE
; O
symptoms O
due O
to O
extreme O
heat B-PHE

-DOCSTART- O


the O
steaming B-PHE
of I-PHE
bone I-PHE
and O
tidal O
fever B-PHE

-DOCSTART- O


1 O
Byak-angelicin O
contained O
in O
its O
root O
can O
dilate O
the O
coronary B-PHE
arteries I-PHE
. O

2 O
Stimulating O
the O
respiratory B-PHE
center I-PHE
, O
vasomotor B-PHE
center I-PHE
and O
nervus B-PHE
vagus I-PHE
. O

3 O
Its O
decoction O
exerts O
bacteriostatic B-PHE
effect I-PHE
. O

4 O
Imperatorin O
, O
another O
active O
component O
, O
is O
effective O
for O
psoriasis B-PHE
. O

-DOCSTART- O


Intelligence B-PHE
, O
Mental B-PHE
state I-PHE
and I-PHE
performance I-PHE
, O
Others O

-DOCSTART- O


Its O
volatile O
oil O
is O
an O
expectorant O
and O
antiasthmatic. O
. O

-DOCSTART- O


This O
is O
a O
symptom O
that O
the O
body O
becomes O
haggard B-PHE
because O
of O
exhaustion B-PHE
syndrome I-PHE
. O

-DOCSTART- O


To O
pacify O
the O
liver B-PHE
and O
subdue O
the O
yang O
; O

To O
conduct O
rebellious O
qi O
downward O
and O
stop O
vomiting B-PHE
; O

To O
stop O
bleeding B-PHE

-DOCSTART- O


gingivitis B-PHE
; O
epulis B-PHE

-DOCSTART- O


kill O
worms B-PHE

-DOCSTART- O


HER2-overexpressing O
breast B-PHE
cancer I-PHE

-DOCSTART- O


ischuria B-PHE
; O
dysuria B-PHE
; O
retention B-PHE
of I-PHE
urine I-PHE

-DOCSTART- O


Juzentaihoto O
Failed O
to O
Augment O
Antigen-Specific O
Immunity B-PHE
but O
Prevented O
Deterioration B-PHE
of O
Patients' O
Conditions O
in O
Advanced O
Pancreatic B-PHE
Cancer I-PHE
under O
Personalized O
Peptide O
Vaccine O
. O

-DOCSTART- O


To O
break O
blood B-PHE
and O
desolve O
stagnation B-PHE
; O
To O
benefit O
qi O

-DOCSTART- O


Huperzine O
B O
has O
been O
found O
to O
be O
an O
inhibitor O
of O
the O
enzyme B-PHE
acetylcholinesterase I-PHE
. O

This O
is O
the O
same O
mechanism O
of O
action O
of O
pharmaceutical O
drugs O
such O
as O
galantamine O
and O
donepezil O
used O
to O
treat O
Alzheimer's B-PHE
disease I-PHE
. O

-DOCSTART- O


Effects O
of O
Hachimijiogan O
on O
dopamine O
, O
serotonin O
and O
vasoactive O
intestinal O
peptide O
in O
plasma O
and O
hypothalamus O
in O
sulpiride-induced O
hyperprolactinemic O
rats O
. O

-DOCSTART- O


Chronic B-PHE
Heart I-PHE
Failure I-PHE

-DOCSTART- O


Treatment O
of O
carbuncle B-PHE
and O
boil B-PHE
at O
the O
early O
stage O
or O
formation B-PHE
of I-PHE
abscess I-PHE
difficult O
to O
burst B-PHE
, O
external O
use O
for O
scabies B-PHE
and O
leprosy B-PHE
. O

-DOCSTART- O


oppressed B-PHE
feeling I-PHE
and O
fullness B-PHE
in O
the O
chest O
and O
diaphragm O

-DOCSTART- O


Spontaneous O
external B-PHE
bleeding I-PHE
, O
hematochezia B-PHE
, O
headache B-PHE
, O
dizziness B-PHE
and O
dim B-PHE
vision I-PHE
, O
red B-PHE
eyes I-PHE
, O
night B-PHE
blindness I-PHE
, O
diabetes B-PHE
mellitus I-PHE
, O
fecal B-PHE
stoppage I-PHE
, O
hemorrhoids B-PHE
. O

-DOCSTART- O


warm B-PHE
malaria I-PHE
; O

pyrexial B-PHE
malaria I-PHE

-DOCSTART- O


Enduring O
cough B-PHE
and O
asthma B-PHE
, O
bronchitis B-PHE
, O
lumbago B-PHE
and O
limp O
leg B-PHE
, O
frequent O
urination B-PHE
, O
enuresis B-PHE
, O
impotence B-PHE
, O
emission B-PHE
, O
intestinal B-PHE
dry I-PHE
and O
constipation B-PHE
, O
stone B-PHE
strangury I-PHE
, O
sores B-PHE
and O
scrofula B-PHE
. O

-DOCSTART- O


Cancer B-PHE

-DOCSTART- O


To O
dispel O
wind B-PHE
and O
effuse O
sweat B-PHE
, O
dissipate O
cold B-PHE
and O
dry O
damp B-PHE
. O

-DOCSTART- O


snake-bite B-PHE

-DOCSTART- O


Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Protective O
immunity B-PHE

-DOCSTART- O


To O
astringe O
intestines B-PHE
and O
check O
diarrhea B-PHE
, O
resolve O
toxin B-PHE
, O
relieve O
itch B-PHE
. O

-DOCSTART- O


Ritonavir O
inhibits O
the O
HIV B-PHE
viral I-PHE
proteinase I-PHE
enzyme I-PHE
which O
prevents O
cleavage B-PHE
of I-PHE
the I-PHE
gag-pol I-PHE
polyprotein I-PHE
, O
resulting O
in O
noninfectious O
, O
immature O
viral B-PHE
particles I-PHE
. O

-DOCSTART- O


Wind-cold-damp B-PHE
impediment O
, O
aching B-PHE
pain I-PHE
in O
joints O
, O
arthritis B-PHE
, O
dysmenorrhea B-PHE
, O
skin B-PHE
numbness I-PHE
, O
weakness B-PHE
in I-PHE
limbs I-PHE
, O
jaundice B-PHE
, O
cough B-PHE
, O
knocks B-PHE
and O
falls B-PHE
, O
sores B-PHE
, O
zoster B-PHE
, O
scalds B-PHE
. O

-DOCSTART- O


( O
1 O
) O
hemorrhoids B-PHE
( O
2 O
) O
polyp B-PHE

-DOCSTART- O


damp B-PHE
Pi O
arthritis B-PHE
due O
to O
dampness B-PHE
. O

damp B-PHE
stroke I-PHE
; O

attack O
of O
dampness B-PHE
syndrome I-PHE
due O
to O
attack O
of O
pathogenic B-PHE
factors I-PHE
. O

-DOCSTART- O


1 O
Inhibiting O
the O
growth O
of O
leukemia615 B-PHE
, O
sarcoma180 B-PHE
and O
cervial B-PHE
carcinoma14 I-PHE
in O
mice O
. O
2 O
Relieving O
iodine B-PHE
deficiency I-PHE
and O
goiter B-PHE
in O
experimental O
animals O
. O

-DOCSTART- O


swelling B-PHE
of O
the O
cheek O
; O
parotitis B-PHE

-DOCSTART- O


Bone B-PHE
Marrow I-PHE
Suppression I-PHE

-DOCSTART- O


Eum O
deficiency O
of O
liver O
and O
kidney O
; O
deficiency O
of O
Eum(vital O
essence O
) O
of O
the O
liver O
and O
kidney O

-DOCSTART- O


cough B-PHE
due O
to O
phlegm-damp B-PHE

-DOCSTART- O


Chronic B-PHE
Viral I-PHE
Hepatitis I-PHE
B I-PHE
Without I-PHE
Delta-agent I-PHE

-DOCSTART- O


prolapse B-PHE
of I-PHE
the I-PHE
rectum I-PHE

-DOCSTART- O


Hypertension B-PHE
. O

-DOCSTART- O


Menopausal B-PHE
syndrome I-PHE
marked O
by O
afternoon O
fever B-PHE
, O
excessive B-PHE
sweating I-PHE
, O
dizziness B-PHE
, O
tinnitus B-PHE
, O
insomnia B-PHE
and O
unsteady B-PHE
blood I-PHE
pressure I-PHE
. O

-DOCSTART- O


Uncaria O
Hook O
( O
UH O
) O
alkaloids O
are O
involved O
in O
the O
beneficial O
effects O
of O
Yokukansan O
. O

However O
, O
the O
pharmacokinetics O
of O
UH O
alkaloids O
after O
oral O
administration O
of O
Yokukansan O
has O
not O
yet O
been O
sufficiently O
investigated O
. O

Therefore O
, O
we O
developed O
and O
validated O
a O
sensitive O
and O
specific O
high-performance O
liquid O
chromatography O
with O
tandem O
mass O
spectrometry O
( O
LC/MS/MS O
) O
method O
for O
the O
simultaneous O
quantitation O
of O
seven O
UH O
alkaloids O
( O
corynoxeine O
, O
isocorynoxeine O
, O
rhynchophylline O
, O
isorhynchophylline O
, O
hirsutine O
, O
hirsuteine O
and O
geissoschizine O
methyl O
ether O
) O
in O
rat O
plasma O
and O
brain O
. O

After O
protein O
precipitation O
with O
acetonitrile O
, O
chromatographic O
separation O
was O
performed O
using O
an O
Ascentis O
Express O
RP-amide O
column O
, O
with O
gradient O
elution O
with O
0.002 O
formic O
acid O
and O
acetonitrile O
at O
0.3 O
mL/min O
. O

All O
analytes O
in O
the O
plasma O
and O
brain O
showed O
good O
linearity O
over O
a O
wide O
concentration O
range O
(r O
> O
0.995 O
) O
. O

Intra-day O
and O
inter-day O
variations O
of O
each O
constituent O
were O
8.6 O
and O
0.08 O
or O
less O
in O
the O
plasma O
, O
and O
14.9 O
and O
0.15 O
or O
less O
in O
the O
brain O
, O
respectively O
. O

The O
validated O
LC/MS/MS O
method O
was O
applied O
in O
the O
pharmacokinetic O
studies O
of O
UH O
alkaloids O
after O
oral O
administration O
of O
Yokukansan O
to O
rats O
. O

In O
the O
plasma O
, O
rhynchophylline O
, O
hirsutine O
, O
hirsuteine O
and O
geissoschizine O
methyl O
ether O
were O
detected O
, O
but O
only O
geissoschizine O
methyl O
ether O
was O
detected O
in O
the O
brain O
. O

These O
results O
suggest O
that O
geissoschizine O
methyl O
ether O
is O
an O
important O
constituent O
of O
the O
pharmacological O
effects O
of O
Yokukansan O
. O

-DOCSTART- O


nausea B-PHE
without O
vomiting B-PHE
. O

-DOCSTART- O


1 O
Oral O
administration O
increases O
the O
level O
of O
cAMP B-PHE
and O
decrease O
the O
level B-PHE
of I-PHE
cGMP I-PHE
in O
plasma O
and O
in O
leukocytes O
. O
Protect O
the O
liver B-PHE
from O
damage O
. O
Hypotensive B-PHE
. O

-DOCSTART- O


Drug B-PHE
Induced I-PHE
Hepatotoxicity I-PHE

-DOCSTART- O


12-0-tetradecanoyl-phorbol-13-acetate O
isolated O
from O
its O
croton O
oil O
is O
a O
cancerigenic B-PHE
component I-PHE
. O

-DOCSTART- O


To O
desolve O
phlegm B-PHE
and O
soften O
hardness O
; O
To O
revitalize O
blood B-PHE

-DOCSTART- O


Some O
patients O
with O
major B-PHE
depressive I-PHE
disorder I-PHE
( O
MDD B-PHE
) O
do O
not O
show O
remission O
of O
their O
depressive O
symptomatology O
. O

We O
investigated O
the O
efficacy O
of O
Rokumigan O
( O
TJ-87 O
) O
and O
Hachimijiogan O
( O
TJ-7 O
) O
in O
20 O
patients O
with O
prolonged O
partial O
remitted O
MDD B-PHE
associated O
with O
fatigue B-PHE
or O
loss B-PHE
of I-PHE
energy I-PHE
. O

In O
these O
20 O
patients O
, O
TJ-7 O
or O
TJ-87 O
was O
added O
to O
the O
previous O
regimen O
for O
4 O
weeks O
. O

Six O
patients O
were O
'much O
improved' O
, O
six O
were O
'minimally O
improved' O
( O
responders O
) O
, O
and O
eight O
showed O
'no O
change' O
( O
non-responders O
) O
, O
on O
the O
Clinical O
Global O
Impression O
Global O
Improvement O
scale O
. O

All O
responders O
had O
Shofuku-fujin O
( O
tenderness B-PHE
or O
weakness B-PHE
of O
the O
lower O
abdomen O
) O
. O

In O
conclusion O
, O
we O
experienced O
12 O
outpatients O
with O
prolonged O
partial O
remitted O
MDD B-PHE
with O
fatigue B-PHE
or O
loss B-PHE
of I-PHE
energy I-PHE
, O
which O
was O
successfully O
treated O
with O
TJ-87 O
or O
TJ-7 O
. O

-DOCSTART- O


Treament O
of O
chronic B-PHE
bronchitis I-PHE
. O

-DOCSTART- O


Kidney B-PHE
Diseases I-PHE

-DOCSTART- O


Efficacy O
of O
Keishibukuryogan O
, O
a O
traditional O
Japanese O
herbal O
medicine O
, O
in O
treating O
cold B-PHE
sensation I-PHE
and O
numbness B-PHE
after O
stroke B-PHE
: O
clinical O
improvement O
and O
skin O
temperature O
normalization O
in O
22 O
stroke B-PHE
patients O
. O

-DOCSTART- O


Urinary B-PHE
systems I-PHE
, O
Urinary B-PHE
system I-PHE
health I-PHE

-DOCSTART- O


Investigated O
for O
use O
/ O
treatment O
in O
bladder B-PHE
cancer I-PHE
. O

-DOCSTART- O


Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Evacuation B-PHE

-DOCSTART- O


distribution O
) O
, O
energy O
supply O
and O
recovery O
, O
Mental B-PHE
state I-PHE
and O
performance O
, O
Man O

-DOCSTART- O


Thoracic O
Surgery O

-DOCSTART- O


wind B-PHE
syndrome I-PHE

-DOCSTART- O


Carotid B-PHE
Artery I-PHE
Stenosis I-PHE

-DOCSTART- O


To O
dispel O
wind B-PHE
and O
relieve O
pain B-PHE
, O
resolve O
toxin B-PHE
and O
disperse O
swelling B-PHE
. O

-DOCSTART- O


Infant B-PHE
, I-PHE
Diabetic I-PHE
Mother I-PHE

-DOCSTART- O


Treament O
of O
heat B-PHE
in O
the O
lung O
with O
cough B-PHE
, O
sticky B-PHE
and I-PHE
bloody I-PHE
sputum I-PHE
, O
and O
distress B-PHE
in I-PHE
the I-PHE
chest I-PHE
. O

-DOCSTART- O


HGS-TR2J O
binds O
TRAIL O
Receptor O
2 O
with O
high O
affinity O
, O
induces O
apoptosis B-PHE
and O
has O
anti-tumor B-PHE
activity I-PHE
, O
both O
as O
a O
single O
agent O
and O
in O
combination O
with O
chemotherapy O
. O

HGS-TR2J O
mimics O
the O
activity O
of O
native O
TRAIL O
( O
tumor O
necrosis O
factor-related O
apoptosis-inducing O
ligand O
) O
and O
, O
thus O
, O
is O
considered O
an O
agonistic O
antibody B-PHE
. O

Numerous O
nonclinical O
studies O
have O
shown O
that O
cell O
lines O
derived O
from O
a O
broad O
array O
of O
solid O
and O
hematological B-PHE
human I-PHE
tumors I-PHE
, O
including O
lung O
, O
colon O
, O
breast O
, O
multiple O
myeloma B-PHE
, O
prostate O
and O
pancreas O
, O
are O
sensitive O
to O
killing O
by O
apoptosis B-PHE
( O
programmed O
cell B-PHE
death I-PHE
) O
induced O
by O
native O
TRAIL O
or O
by O
agonistic O
antibodies O
to O
TRAIL O
Receptors O
1 O
and O
2.2-24 O
. O

-DOCSTART- O


Tiagabine O
blocks O
GABA O
uptake O
into O
presynaptic O
neurons O
, O
permitting O
more O
GABA O
to O
be O
available O
for O
receptor O
binding O
on O
the O
surfaces O
of O
post-synaptic O
cells O
. O

Gabapentin's O
therapeutic O
action O
on O
neuropathic B-PHE
pain I-PHE
is O
thought O
to O
involve O
voltage-gated O
N-type O
calcium O
ion O
channels O
. O

It O
is O
thought O
to O
bind O
to O
the O
subunit O
(1 O
and O
2) O
of O
the O
voltage-dependent O
calcium O
channel O
in O
the O
central B-PHE
nervous I-PHE
system I-PHE
. O

-DOCSTART- O


wind B-PHE
one O
of O
the O
five O
pathogenic O
factors O
, O
also O
one O
of O
the O
six O
exogenous O
pathogenic O
factors O
which O
often O
causes O
disease B-PHE
in O
association O
with O
other O
pathogenic O
agent O
. O

It O
is O
of O
Yang O
nature O
and O
apt O
to O
change O
, O
resulting O
symptoms O
are O
usually O
migratory O
and O
variable O
. O

-DOCSTART- O


1 O
To O
clear O
heat B-PHE
and O
toxic O
material O
. O

2 O
To O
clear O
liver-heat B-PHE
to O
treat O
eye B-PHE
disease I-PHE
. O

3 O
To O
clear O
dampness-heat B-PHE
. O

-DOCSTART- O


Iohexol O
ia O
used O
in O
myelography O
, O
arthrography O
, O
nephroangiography O
, O
arteriography O
, O
and O
other O
radiographic O
procedures O
. O

-DOCSTART- O


exogenous O
exogenous B-PHE
febrile I-PHE
disease I-PHE
; O

syndrome B-PHE
of I-PHE
T'aeyang I-PHE
meridian I-PHE
affected O
by O
the O
wind B-PHE

affection O
by O
cold B-PHE
; O

common B-PHE
cold I-PHE

-DOCSTART- O


Glomerulonephritis O

-DOCSTART- O


blurred B-PHE
vision I-PHE

-DOCSTART- O


To O
strengthen O
spleen B-PHE
and O
benefit O
qi O
; O
To O
soothe O
liver B-PHE
and O
modulate O
qi O
; O
To O
revitalize O
blood B-PHE
and O
desolve O
stagnation B-PHE

-DOCSTART- O


Treament O
of O
abdomen B-PHE
pain I-PHE
due O
to O
intestinal B-PHE
worms I-PHE
, O
sores B-PHE
, O
uterine B-PHE
bleeding I-PHE
( O
drug O
carbonizing O
) O
. O

-DOCSTART- O


irregular O
chills B-PHE
and I-PHE
fever I-PHE

-DOCSTART- O


unblock O
blood B-PHE

-DOCSTART- O


Treatment O
of O
chills B-PHE
, O
fever B-PHE
and O
headache B-PHE
in O
colds B-PHE
and O
influenza B-PHE
, O
vexation B-PHE
, O
oppressed B-PHE
feeling I-PHE
in O
the O
chest O
and O
insomnia B-PHE
. O

-DOCSTART- O


Kidney B-PHE
Failure I-PHE
, I-PHE
Chronic I-PHE

-DOCSTART- O


This O
is O
an O
external B-PHE
wound I-PHE
in I-PHE
muscle I-PHE
of I-PHE
waist I-PHE
. O

-DOCSTART- O


Yin O
Chen O
Hao O
Tang O
( O
YCHT O
) O
is O
one O
of O
the O
most O
frequently O
used O
prescriptions O
in O
the O
long O
history O
of O
traditional O
Chinese O
medicine O
practice O
. O

The O
prescription O
contains O
three O
Chinese O
herbs O
, O
namely O
Artemisia O
capillaries O
Thunb O
. O

( O
Compositae O
) O
, O
Rheum O
officinale O
Baillon O
( O
Polygonaceae O
) O
, O
and O
Gardenia O
jasminoids O
Ellis O
( O
Rubiaceae O
) O
, O
and O
has O
been O
widely O
used O
to O
treat O
acute B-PHE
hepatitis I-PHE
with O
jaundice B-PHE
. O

In O
this O
study O
, O
the O
in O
vitro O
anti-HSV-1 B-PHE
and I-PHE
HSV-2 I-PHE
activities I-PHE
of O
the O
water O
extract O
of O
YCHT O
were O
investigated O
. O

Results O
showed O
that O
YCHT O
water O
extract O
inhibited O
both O
HSV-1 B-PHE
and I-PHE
HSV-2 I-PHE
infections I-PHE
. O

However O
, O
the O
inhibition O
was O
more O
effective O
against O
HSV-2 B-PHE
than O
against O
HSV-1 B-PHE
. O

The O
IC(50 O
) O
and O
IC(90 O
) O
values O
of O
YCHT O
water O
extract O
against O
HSV-1 B-PHE
infection I-PHE
were O
in O
the O
range O
of O
142.5-150.1 O
and O
191.3-393.9 O
microg/ml O
, O
and O
against O
HSV-2 B-PHE
infection I-PHE
they O
were O
in O
the O
range O
of O
19.6-29.4 O
and O
42.2-97.7 O
microg/ml O
, O
respectively O
. O

The O
water O
extract O
of O
YCHT O
showed O
no O
cytotoxic O
effect O
at O
a O
concentration O
of O
500 O
microg/ml O
or O
below O
, O
and O
had O
a O
CC(50 O
) O
value O
of O
850.7+/-1.7 O
microg/ml O
. O

The O
prescription O
was O
found O
to O
diminish O
HSV-2 B-PHE
infectivity I-PHE
in O
a O
dose-dependent O
manner O
, O
and O
the O
activity O
was O
influenced O
by O
the O
incubation O
periods O
and O
the O
incubation O
temperatures O
. O

Concurrent O
addition O
of O
virus O
with O
YCHT O
or O
pre-treatment O
of O
the O
virus O
with O
the O
prescription O
extract O
both O
protected O
the O
cells O
from O
infection B-PHE
. O

In O
summary O
, O
the O
water O
extract O
of O
YCHT O
was O
concluded O
to O
inhibit O
infections B-PHE
by O
HSV-1 B-PHE
and O
HSV-2 B-PHE
and O
this O
effect O
was O
likely O
mediated O
through O
direct O
inactivation O
of O
the O
virus B-PHE
infectivity I-PHE
. O

-DOCSTART- O


red-white O
dysentery B-PHE

-DOCSTART- O


To O
control O
the O
essence O
; O

To O
astringe O
the O
intestines B-PHE
and O
stop O
diarrhea B-PHE
; O

To O
decrease O
urination B-PHE

-DOCSTART- O


Treatment O
of O
edema B-PHE
with O
oliguria B-PHE
, O
dizziness B-PHE
and O
palpitation B-PHE
caused O
by O
retained O
fluid O
, O
diminished O
function O
of O
the O
spleen B-PHE
marked O
by O
anorexia B-PHE
, O
loose O
stools B-PHE
or O
diarrhea B-PHE
, O
restlessness B-PHE
and O
insomnia B-PHE
. O

-DOCSTART- O


disperse O
stasis B-PHE

-DOCSTART- O


clear O
( O
pathogenic O
) O
fire B-PHE
and O
invigorate O
blood B-PHE

-DOCSTART- O


Intravenous O
Anesthetic O
Interaction O
Unrecognized B-PHE
Condition I-PHE

-DOCSTART- O


Coronary B-PHE
heart I-PHE
disease I-PHE
, O
angina B-PHE
pectoris I-PHE
, O
hypercholesterolemia B-PHE
, O
Parkinson B-PHE
disease I-PHE
, O
peripheral B-PHE
arterial I-PHE
diseases I-PHE
, O
chest B-PHE
impediment I-PHE
and O
heart B-PHE
pain I-PHE
, O
cough B-PHE
of O
phlegm B-PHE
asthma B-PHE
, O
diarrhea B-PHE
and O
dysentery B-PHE
, O
vaginal B-PHE
discharge I-PHE
, O
emission B-PHE
, O
retinal B-PHE
insufficiency I-PHE
syndrome I-PHE
. O

-DOCSTART- O


nine O
kinds O
of O
illness B-PHE
due O
to O
disturbance O
of O
Gi O

-DOCSTART- O


Endometriosis B-PHE

-DOCSTART- O


Treatment O
of O
scrotal B-PHE
hernia I-PHE
with O
pain B-PHE
and O
cold B-PHE
extremities I-PHE
, O
dysmenorrhea B-PHE
with O
lower O
abdominal B-PHE
pain I-PHE
and O
cold B-PHE
sensation I-PHE
, O
distending B-PHE
pain I-PHE
in I-PHE
the I-PHE
epigastrium I-PHE
with O
anorexia B-PHE
, O
vomiting B-PHE
and O
diarrhea B-PHE
, O
hydrocele B-PHE
of O
tunica O
vaginalis O
. O

Fructus O
Foeniculi O
( O
processed O
with O
salt O
) O
: O
Scrotal B-PHE
hernia I-PHE
with O
pain B-PHE
and O
cold B-PHE
extremities I-PHE
, O
dysmenorrhea B-PHE
with O
abdominal B-PHE
pain I-PHE
caused O
by O
cold B-PHE
. O

-DOCSTART- O


Woman O
, O
Bone B-PHE
Health I-PHE
and O
Osteoporosis B-PHE
, O
Bone B-PHE
metabolism I-PHE
/ I-PHE
density I-PHE
, O
Menopausal B-PHE
woman I-PHE

-DOCSTART- O


Small O
dosage O
of O
berberine O
enhances O
the O
action B-PHE
of I-PHE
acetylcholine I-PHE
on O
animals' O
hearts O
in O
vitro O
, O
while O
large O
dosage O
counteracts O
it O
. O

-DOCSTART- O


To O
contract O
uterus O
and O
stanch O
bleeding O
, O
relieve O
pain O
. O

-DOCSTART- O


insulin B-PHE
sensitivity I-PHE
and O
diabetes B-PHE
risk O
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Woman O
, O
Physical O
performance O
and O
fitness O
, O
Improvement O
of O
blood B-PHE
glucose I-PHE
levels I-PHE
, O
absorption B-PHE
, O
Others O
, O
Body O
weight O
regulation O
, O
General O
woman O
, O
Strength O
and O
power O
, O
Digestion B-PHE
, O
Hypersensitivity B-PHE
, O
motility B-PHE

-DOCSTART- O


Treatment O
of O
cough B-PHE
, O
itching B-PHE
of O
the O
throat O
and O
profuse O
expectoration B-PHE
in I-PHE
colds I-PHE
, O
nausea B-PHE
, O
vomiting B-PHE
and O
epigastric B-PHE
distension I-PHE
caused O
by O
improper O
diet O
or O
excessive O
drinking O
. O

-DOCSTART- O


Hepatocellular B-PHE
Carcinoma I-PHE

-DOCSTART- O


shortness B-PHE
of I-PHE
breath I-PHE
with O
chest B-PHE
congested I-PHE

-DOCSTART- O


To O
regulate O
the O
flow O
of O
qi O
in O
the O
liver B-PHE
, O
spleen B-PHE
and O
stomach B-PHE
, O
and O
to O
resolve O
phlegm B-PHE
. O

-DOCSTART- O


Treatment O
of O
fever B-PHE
due O
to O
deficiency B-PHE
of O
yin O
, O
consumptive O
fever B-PHE
, O
fever B-PHE
in O
infantile O
malnutrition B-PHE
. O

-DOCSTART- O


The O
resin O
is O
a O
strong O
anion O
exchange O
resin O
, O
which O
means O
that O
it O
can O
exchange O
its O
chloride O
anions O
with O
anionic B-PHE
bile I-PHE
acids I-PHE
in O
the O
gastrointestinal B-PHE
tract I-PHE
and O
bind O
them O
strongly O
in O
the O
resin O
matrix O
. O

-DOCSTART- O


For O
the O
treatment O
of O
Tuberculosis B-PHE
and O
Tuberculosis-related O
mycobacterial B-PHE
infections I-PHE
. O

-DOCSTART- O


Breast B-PHE
Neoplasms I-PHE

-DOCSTART- O


a O
mass O
amount O
of O
phlegm B-PHE
, O
and O
dyspnea B-PHE
and O
cough B-PHE

-DOCSTART- O


damp B-PHE
Pi I-PHE
syndrome I-PHE
; O
arthritis B-PHE
due O
to O
dampness B-PHE
; O
damp B-PHE
impediment O
[ O
blockage B-PHE
] O

-DOCSTART- O


distension B-PHE
and O
fullness B-PHE

-DOCSTART- O


To O
arrest O
discharges O
, O
promote O
healing O
of O
wounds B-PHE
and O
tissue B-PHE
regeneration I-PHE
, O
and O
alleviate O
pain B-PHE
. O

-DOCSTART- O


In O
traditional O
Chinese O
medicine O
theory O
( O
TCM O
) O
, O
the O
affected O
parts O
of O
sprains B-PHE
, O
bruises B-PHE
and O
arthritis B-PHE
are O
considered O
to O
be O
under O
certain O
conditions O
of O
TCM O
concept O
. O

We O
administered O
two O
Kampo O
medicines O
with O
synergistic O
effects O
to O
promote O
quick O
recovery I-PHE
from O
these O
conditions O
. O

Jidabokuippo O
( O
Zhidapuyifang O
in O
Chinese O
) O
, O
which O
means O
'decoction O
for O
contusions' B-PHE
is O
expected O
to O
remove O
these O
conditions O
. O

Hachimijiogan O
( O
Baweidihuangwan O
in O
Chinese O
) O
, O
which O
translates O
as O
'eight-ingredient O
pill O
with O
Rehmannia' O
is O
expected O
to O
restore O
presumed O
minute O
bone B-PHE
injury I-PHE
and O
regulates O
bone B-PHE
metabolism I-PHE
by O
changing O
such O
conditions O
based O
on O
TCM O
theory O
. O

We O
administered O
the O
two O
prescriptions O
to O
10 O
patients O
( O
age O
range O
: O
40-85 O
years O
; O
1 O
male O
, O
9 O
females O
) O
suffering O
from O
bruises B-PHE
, O
sprains B-PHE
, O
arthritis B-PHE
and O
spinal B-PHE
compression I-PHE
fracture I-PHE
without O
changing O
their O
routine O
intake O
of O
other O
drugs O
. O

Patients O
reported O
on O
changes O
in O
the O
pain O
of O
affected O
body O
parts O
by O
using O
the O
visual O
analog O
scale O
( O
VAS O
) O
before O
and O
after O
administration O
of O
Kampo O
medicine O
. O

In O
almost O
all O
cases O
, O
recovery B-PHE
began O
promptly O
after O
administration O
and O
the O
pain B-PHE
disappeared O
within O
approximately O
2 O
weeks O
. O

Large O
doses O
for O
a O
short O
time O
brought O
about O
much O
quicker O
recovery B-PHE
than O
small O
doses O
. O

Administration O
of O
a O
combination O
of O
two O
Kampo O
medicines O
, O
Jidabokuippo O
and O
Hachimijiogan O
, O
quickly O
resolved O
the O
pain B-PHE
of O
bruises B-PHE
, O
sprains B-PHE
, O
arthritis B-PHE
and O
one O
spinal B-PHE
compression I-PHE
fracture I-PHE
. O

-DOCSTART- O


Treament O
of O
spitting B-PHE
of I-PHE
blood I-PHE
, O
epistaxis B-PHE
, O
abnormal B-PHE
uterine I-PHE
bleeding I-PHE
, O
traumatic B-PHE
bleeding I-PHE
, O
amenorrhea B-PHE
with O
blood O
stasis O
, O
arthralgia B-PHE
, O
traumatic O
swelling B-PHE
and O
pain B-PHE
. O

-DOCSTART- O


1 O
To O
clear O
the O
lungs B-PHE
and O
tonify O
yin O
; O
2 O
To O
strengthen O
the O
stomach B-PHE
and O
promote O
the O
production B-PHE
of I-PHE
body I-PHE
fluids I-PHE

-DOCSTART- O


Sumatriptan O
is O
a O
serotonin O
agonist O
that O
acts O
selectively O
at O
5HT1 O
receptors O
. O

Naproxen O
inhibits O
the O
activity B-PHE
of I-PHE
the I-PHE
enzymes I-PHE
cyclo-oxygenase I-PHE
I I-PHE
and I-PHE
II I-PHE
, O
resulting O
in O
a O
decreased O
formation B-PHE
of I-PHE
precursors I-PHE
of I-PHE
prostaglandins I-PHE
and I-PHE
thromboxanes I-PHE
. O

-DOCSTART- O


Melphalan O
alkylates O
DNA B-PHE
at O
the O
N7 O
position O
of O
guanine O
and O
induces O
DNA B-PHE
inter-strand I-PHE
cross-linkages I-PHE
, O
resulting O
in O
the O
inhibition O
of O
DNA B-PHE
and I-PHE
RNA I-PHE
synthesis I-PHE
and O
cytotoxicity B-PHE
against O
both O
dividing O
and O
non-dividing O
tumor B-PHE
cells I-PHE
. O

-DOCSTART- O


1 O
Its O
alcoholic O
extract O
exerts O
antipyretic O
and O
analgesic O
effect O
. O

2 O
Its O
aqueous O
extract O
is O
a O
cardiotonic O
. O

-DOCSTART- O


Neuromyelitis B-PHE
Optica I-PHE
( O
NMO B-PHE
) O
and O
NMO B-PHE
Spectrum I-PHE
Disorder I-PHE
( O
NMOSD B-PHE
) O

-DOCSTART- O


restrain O
acid B-PHE

-DOCSTART- O


warm O
the O
lumbus B-PHE
and O
knees B-PHE

-DOCSTART- O


night O
fever B-PHE
and O
chilling B-PHE
in O
the O
morning O

-DOCSTART- O


strengthen O
sinews B-PHE
and O
bones B-PHE

-DOCSTART- O


Fluticasone O
, O
a O
synthetic O
trifluorinated O
glucocorticoid O
receptor O
agonist O
with O
antiallergic O
, O
anti-inflammatory O
and O
antipruritic O
effects O
. O

GSK2190915 O
, O
a O
potent O
5-lipoxygenase-activating O
protein O
inhibitor O
, O
prevents O
the O
synthesis B-PHE
of I-PHE
leukotrienes I-PHE
and O
5-oxo-6,8,11,14-eicosatetraenoic O
acid O
( O
5-oxo-ETE O
) O
. O

-DOCSTART- O


Others O

-DOCSTART- O


Quality O
of O
life O
, O
Others O

-DOCSTART- O


To O
diffuse O
lung O
qi O
, O
dispel O
wind-damp B-PHE
, O
disperse O
swelling B-PHE
toxin I-PHE
. O

-DOCSTART- O


Pneumonia B-PHE
, O
pyothorax B-PHE
, O
sore B-PHE
pharynx I-PHE
, O
oral B-PHE
ulcer I-PHE
, O
vesical B-PHE
calculus I-PHE
, O
swollen O
welling O
abscess B-PHE
. O

-DOCSTART- O


Doxorubicin O
forms O
complexes O
with O
DNA O
by O
intercalation O
between O
base O
pairs O
, O
and O
it O
inhibits O
topoisomerase B-PHE
II I-PHE
activity I-PHE
by O
stabilizing O
the O
DNA-topoisomerase B-PHE
II I-PHE
complex O
, O
preventing O
the O
religation O
portion O
of O
the O
ligation-religation O
reaction O
that O
topoisomerase B-PHE
II I-PHE
catalyzes I-PHE
. O

-DOCSTART- O


Gout B-PHE

-DOCSTART- O


Yokukansan O
( O
YKS O
) O
is O
a O
traditional O
Japanese O
medicine O
consisting O
of O
seven O
medicinal O
herbs O
that O
is O
used O
for O
the O
treatment O
of O
neurosis B-PHE
, O
insomnia B-PHE
, O
and O
the O
behavioral/psychological O
symptoms O
of O
dementia B-PHE
. O

This O
study O
examined O
the O
effects O
of O
YKS O
on O
morphine O
tolerance O
and O
physical O
dependence O
in O
mice O
. O

Daily O
oral O
administration O
of O
YKS O
( O
0.5 O
or O
1 O
g/kg O
) O
for O
3 O
weeks O
significantly O
attenuated O
morphine O
tolerance O
and O
naloxone-precipitated O
morphine O
withdrawal O
signs O
( O
jumps O
and O
body O
weight O
loss O
) O
without O
affecting O
the O
analgesic O
effect O
of O
morphine O
. O

The O
inhibitory O
effect O
of O
YKS O
on O
withdrawal O
jumps O
in O
morphine-dependent O
mice O
was O
blocked O
by O
a O
single O
pretreatment O
with O
an O
a(2)-adrenoceptor O
antagonist O
, O
yohimbine O
, O
but O
not O
by O
an O
a(1)-adrenoceptor O
antagonist O
, O
prazosin O
. O

A O
similar O
inhibitory O
effect O
on O
withdrawal O
jumps O
was O
observed O
by O
repeated O
administration O
of O
yohimbine O
. O

The O
membrane O
expression O
of O
a(2A)-adrenoceptors O
in O
the O
pons/medulla O
was O
decreased O
in O
morphine O
withdrawn O
animals O
; O
this O
reduction O
was O
prevented O
by O
repeated O
administration O
of O
YKS O
or O
yohimbine O
. O

Competitive O
radioligand O
and O
[(35)S]guanosine-5'-O-(3-thiotriphosphate O
) O
binding O
assays O
revealed O
that O
YKS O
and O
its O
constituent O
herbs O
, O
Glycyrrhiza O
( O
GR O
) O
and O
Uncaria O
hook O
( O
UH O
) O
, O
had O
specific O
binding O
affinity O
for O
and O
antagonist O
activity O
against O
the O
a(2A)-adrenoceptor O
. O

Certain O
chemical O
constituents O
, O
including O
GR O
- O
derived O
glycyrrhizin O
and O
its O
metabolite O
, O
18b-glycyrrhetinic O
acid O
, O
and O
UH-derived O
geissoschizine O
methyl O
ether O
( O
GME O
) O
, O
shared O
such O
activities O
. O

Repeated O
administration O
of O
GR O
, O
UH O
, O
glycyrrhizin O
or O
GME O
significantly O
inhibited O
morphine O
withdrawal O
signs O
. O

These O
results O
suggest O
that O
YKS O
and O
its O
active O
constituents O
inhibit O
morphine O
tolerance O
and O
physical O
dependence O
, O
and O
that O
the O
latter O
is O
due O
at O
least O
in O
part O
to O
the O
prevention O
of O
the O
decreased O
membrane O
expression O
of O
the O
a(2A)-adrenoceptor O
in O
the O
brainstem O
by O
its O
prolonged O
blockade O
. O

-DOCSTART- O


Effects O
of O
Yokukansan O
, O
a O
traditional O
Japanese O
medicine O
, O
on O
thiamine B-PHE
deficiency I-PHE
( O
TD B-PHE
) O
- O
induced O
decrease O
of O
glutamate O
uptake O
were O
examined O
in O
cultured O
rat O
cortical O
astrocytes O
. O

Yokukansan O
( O
100 O
- O
500 O
microg O
/ O
ml O
) O
ameliorated O
the O
TD B-PHE
- O
induced O
decrease O
in O
glutamate O
uptake O
by O
astrocytes B-PHE
, O
implying O
that O
yokukansan O
may O
contain O
active O
herbs O
and O
compounds O
possessing O
this O
effect O
. O

Among O
the O
seven O
constituent O
herbs O
of O
yokukansan O
, O
significant O
effects O
were O
found O
for O
glycyrrhiza O
. O

Furthermore O
, O
glycyrrhizin O
and O
its O
metabolite O
18 O
beta O
- O
glycyrrhetinic O
acid O
( O
10(-7)-10(-4)M O
) O
, O
among O
the O
eight O
components O
of O
glycyrrhiza O
, O
ameliorated O
the O
TD B-PHE
- O
induced O
decrease O
of O
glutamate O
uptake O
in O
astrocytes O
in O
a O
concentration O
- O
dependent O
manner O
. O

These O
substances O
inhibited O
protein B-PHE
kinase I-PHE
C I-PHE
( O
PKC B-PHE
) O
activity O
under O
the O
in O
vitro O
conditions O
. O

These O
lines O
of O
evidence O
suggest O
that O
glycyrrhizin O
, O
a O
main O
component O
of O
glycyrrhiza O
, O
and O
its O
metabolite O
18 O
beta O
- O
glycyrrhetinic O
acid O
are O
likely O
responsible O
for O
amelioration O
of O
dysfunction O
of O
glutamate O
transport O
in O
astrocytes O
. O

The O
inhibition O
of O
the O
PKC B-PHE
activity I-PHE
might O
be O
related O
to O
the O
pharmacological O
efficacy O
of O
these O
substances O
. O

-DOCSTART- O


Effects O
of O
tokishakuyakusan O
, O
Keishibukuryogan O
and O
Unkeito O
on O
DNA B-PHE
polymerase I-PHE
alpha I-PHE
activity I-PHE
in O
uteri O
of O
pregnant O
mare's O
serum O
gonadotropin-treated O
immature O
rats O
. O

-DOCSTART- O


warm O
the O
lung B-PHE

-DOCSTART- O


This O
is O
a O
transmission O
of O
pathogenic O
factor O
of O
pyogenic B-PHE
febrile I-PHE
disease I-PHE
from O
Taeyanggyeong O
to O
Yangmyeonggyeong O
. O

-DOCSTART- O


support O
five O
viscera B-PHE

-DOCSTART- O


disperse O
accumulation B-PHE
and O
relieve O
pain B-PHE

-DOCSTART- O


Atrophy B-PHE

-DOCSTART- O


Taxation B-PHE
damage I-PHE
and O
sinew B-PHE
bone I-PHE
pain I-PHE
, O
impotence B-PHE
, O
stomachache B-PHE
, O
innominate B-PHE
toxin I-PHE
swelling I-PHE
, O
knife B-PHE
wound I-PHE
. O

-DOCSTART- O


Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Kids O
, O
Others O
, O
Fetus O

-DOCSTART- O


Corylifolinin O
( O
isobavachalcone O
) O
dilates O
coronary B-PHE
artery I-PHE
significantly O
. O

-DOCSTART- O


A O
symptom O
that O
the O
chest O
is O
heavy O
and O
full O
. O

-DOCSTART- O


abdominal B-PHE
fullness I-PHE
; O
abdominal B-PHE
distension I-PHE

-DOCSTART- O


nourish O
Eum O
( O
Yin O
) O
and O
nourish O
blood B-PHE

-DOCSTART- O


Its O
alcoholic O
extract O
inhibits O
the O
heart B-PHE
and O
lowers O
blood B-PHE
pressure I-PHE
in O
anesthetized O
cats O
. O

-DOCSTART- O


fever B-PHE
with O
dysphoria B-PHE
; O
dysphoria B-PHE
with O
smothery O
sensation O
; O
smothery O
fever B-PHE

-DOCSTART- O


ceruminal B-PHE
impaction I-PHE

-DOCSTART- O


swelling B-PHE
of I-PHE
carbuncle I-PHE
is O
lumped O
at O
the O
neck O

-DOCSTART- O


dizziness B-PHE

-DOCSTART- O


Organophosphate B-PHE
Poisoning I-PHE

-DOCSTART- O


This O
is O
a O
syndrome O
after O
phlegm B-PHE
due O
to O
Wind B-PHE
sidesae O
blocked O
Gi O
. O

-DOCSTART- O


Both O
acted O
at O
the O
same O
active O
site O
of O
penicillinbinding O
protein O
2A O
but O
at O
relatively O
high O
MICs O
of O
32 O
g/ml O
. O

The O
relatively O
high O
MICs O
make O
it O
less O
likely O
for O
both O
drugs O
to O
saturate O
target O
sites O
, O
thereby O
maintaining O
additive O
antibacterial B-PHE
effect I-PHE
. O

-DOCSTART- O


blood B-PHE
wind I-PHE
of O
female O

-DOCSTART- O


cool O
blood B-PHE
and O
stop O
bleeding B-PHE

-DOCSTART- O


Dim B-PHE
vision I-PHE
, O
flooding B-PHE
and O
spotting I-PHE
, O
bleeding I-PHE
due O
to O
external B-PHE
injury I-PHE
, O
sore B-PHE
toxin I-PHE
and O
intractable O
lichen B-PHE
. O

-DOCSTART- O


skin B-PHE
disease I-PHE
on O
palms O
. O

-DOCSTART- O


Ankylosing B-PHE
Spondylitis I-PHE

-DOCSTART- O


hoarseness B-PHE
due O
to O
singing O

-DOCSTART- O


dyspnea B-PHE
with O
coughing B-PHE

-DOCSTART- O


dry O
phlegm B-PHE
; O
dry-phlegm B-PHE
( O
syndrome O
) O

-DOCSTART- O


Delayed O
recovering O
of O
drug O
transport O
barrier O
by O
inhibiting O
the O
synthesis O
of O
barrier O
components O
. O

-DOCSTART- O


Water O
extract O
of O
Samultang O
reduces O
apoptotic B-PHE
cell I-PHE
death I-PHE
by O
h(2)o(2)-induced O
oxidative B-PHE
injury I-PHE
in O
sk-N-mc O
cells O
. O

-DOCSTART- O


carbuncle B-PHE
and O
cellulitis B-PHE
of O
the O
back O
; O

carbuncle B-PHE
on O
the O
back O

-DOCSTART- O


To O
eliminate O
fluid B-PHE
and O
relieve O
edema B-PHE
( O
sthenia-syndrome B-PHE
with O
edema B-PHE
and O
ascites B-PHE
) O
. O

-DOCSTART- O


abdominal B-PHE
mass I-PHE
; O
mass B-PHE
in I-PHE
the I-PHE
abdomen I-PHE

-DOCSTART- O


Wind-evil O
attacked O
meridian O
, O
facial B-PHE
paralysis I-PHE
, O
muscle B-PHE
numbness I-PHE
, O
pain B-PHE
of I-PHE
tendons I-PHE
and I-PHE
bone I-PHE
. O

-DOCSTART- O


For O
ascariasis B-PHE
and O
taeniasis B-PHE
. O

For O
constipation B-PHE
due O
to O
dryness B-PHE
of O
intestine O
. O

-DOCSTART- O


( O
1 O
) O
hematochezia B-PHE
( O
2 O
) O
viginal B-PHE
bleeding I-PHE

-DOCSTART- O


wind B-PHE
rash I-PHE
; O
German B-PHE
measles I-PHE
; O
rubella B-PHE
; O
urticaria B-PHE

-DOCSTART- O


traumatic B-PHE
cataract I-PHE

-DOCSTART- O


Endocrine B-PHE
& I-PHE
reproductive I-PHE
systems I-PHE
, O
Reproductive B-PHE
systems I-PHE
, O
Dermatological B-PHE
systems I-PHE
health I-PHE
, O
Overall O
CVD B-PHE
, O
Diet B-PHE
related I-PHE
cardiovascular I-PHE
disease I-PHE
, O
General O
skin B-PHE
health I-PHE
, O
Others O

-DOCSTART- O


eliminate O
vacuity O
and O
clod O
of O
the O
spleen O
and O
the O
stomach O

-DOCSTART- O


To O
dispel O
wind-damp B-PHE
, O
quicken O
blood B-PHE
and O
relieve O
pain B-PHE
, O
resolve O
toxin B-PHE
. O

-DOCSTART- O


Urinary B-PHE
system I-PHE
health I-PHE
, O
insulin B-PHE
sensitivity I-PHE
and O
diabetes B-PHE
risk I-PHE
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Digestion B-PHE
, O
Urinary B-PHE
system I-PHE
health I-PHE
, O
Improvement O
of O
blood B-PHE
glucose I-PHE
levels I-PHE
, O
absorption B-PHE
, O
Urinary B-PHE
systems I-PHE
, O
Pregnancy B-PHE

-DOCSTART- O


To O
expel O
wind B-PHE
and O
heat B-PHE
, O
purge O
pathogenic O
fire O
and O
relax O
the O
bowels O
. O

-DOCSTART- O


cool O
blood B-PHE

-DOCSTART- O


Neurological B-PHE
systems I-PHE
, O
Neurological B-PHE
systems I-PHE
health I-PHE

-DOCSTART- O


Strength B-PHE
and O
power B-PHE
, O
Physical B-PHE
performance I-PHE
and O
fitness B-PHE

-DOCSTART- O


Intelligence B-PHE
, O
Mental B-PHE
state I-PHE
and I-PHE
performance I-PHE
, O
Memory B-PHE

-DOCSTART- O


Hepatoma B-PHE

-DOCSTART- O


bloody B-PHE
stool I-PHE
; O
hematochezia B-PHE

-DOCSTART- O


To O
invigorate O
blood B-PHE
and O
stop O
pain B-PHE
. O

-DOCSTART- O


Childhood B-PHE
Acute I-PHE
Erythroid I-PHE
Leukemia I-PHE

-DOCSTART- O


Perennial B-PHE
Allergic I-PHE
Rhinitis I-PHE

-DOCSTART- O


Apical B-PHE
Ballooning I-PHE
Syndrome I-PHE

-DOCSTART- O


absorption B-PHE
, O
Gut B-PHE
health I-PHE
and O
immunity B-PHE
, O
Digestion B-PHE
, O
motility O
, O
Evacuation B-PHE

-DOCSTART- O


Overactive B-PHE
Bladder I-PHE
( O
OAB B-PHE
) O

-DOCSTART- O


For O
activating O
blood B-PHE
and O
modulating O
period O

-DOCSTART- O


To O
invigorate O
the O
function B-PHE
of I-PHE
the I-PHE
kidney I-PHE
, O
to O
alleviate O
asthma B-PHE
, O
and O
to O
relieve O
diarrhea B-PHE
. O

-DOCSTART- O


It O
may O
also O
bind O
to O
bacterial B-PHE
potassium I-PHE
transporters I-PHE
, O
thereby O
inhibiting O
their O
function O
. O

-DOCSTART- O


Deficiency O
of O
yin O
of O
the O
liver B-PHE
and O
the O
kidney B-PHE
marked O
by O
tinnitus B-PHE
, O
impairment B-PHE
of I-PHE
hearing I-PHE
, O
dizziness B-PHE
and O
blurred B-PHE
vision I-PHE
. O

-DOCSTART- O


sore B-PHE
of I-PHE
scrotum I-PHE

-DOCSTART- O


Pemetrexed O
binds O
to O
and O
inhibits O
the O
enzyme O
thymidylate B-PHE
synthase I-PHE
which O
catalyses O
the O
substrate O
to O
an O
essential O
precursor O
in O
DNA B-PHE
synthesis I-PHE
. O

Carboplatin O
is O
activated O
intracellularly O
to O
form O
reactive O
platinum O
complexes O
that O
bind O
to O
nucleophilic O
groups O
such O
as O
GC-rich O
sites O
in O
DNA B-PHE
, O
thereby O
inducing O
intrastrand O
and O
interstrand O
DNA B-PHE
cross-links O
, O
as O
well O
as O
DNA-protein B-PHE
cross-links O
. O

By O
binding O
to O
the O
ATP-binding O
site O
, O
enzastaurin O
selectively O
inhibits O
protein B-PHE
kinase I-PHE
C I-PHE
beta I-PHE
, O
which O
appears O
to O
be O
cytotoxic O
in O
cells O
with O
DNA B-PHE
alterations O
or O
DNA O
damage O
which O
may O
decrease O
tumor B-PHE
blood I-PHE
supply I-PHE
, O
preventing O
growth B-PHE
. O

-DOCSTART- O


RK-0202 O
, O
an O
oral O
rinse O
for O
the O
prevention O
and O
treatment O
of O
mucositis B-PHE
, O
is O
based O
on O
the O
company's O
ProGelz O
technology O
and O
is O
comprised O
of O
the O
potent O
antioxidant O
N-acetylcysteine O
in O
a O
polymer O
matrix O
. O

-DOCSTART- O


deficiency O
of O
both O
Gi O
( O
vital O
energy O
) O
and O
blood B-PHE

-DOCSTART- O


Schizophrenia B-PHE
Prodrome I-PHE

-DOCSTART- O


For O
use O
in O
the O
treatment O
of O
symptomatic O
anaemia B-PHE
associated O
with O
chronic B-PHE
renal I-PHE
failure I-PHE
( O
CRF B-PHE
) O
in O
adult O
and O
paediatric O
patients O
. O

Also O
for O
use O
in O
the O
treatment O
of O
anaemia B-PHE
and O
reduction B-PHE
of I-PHE
transfusion I-PHE
requirements O
in O
adult O
patients O
receiving O
chemotherapy O
for O
solid B-PHE
tumours I-PHE
, O
malignant B-PHE
lymphoma I-PHE
or O
multiple B-PHE
myeloma I-PHE
, O
and O
at O
risk O
of O
transfusion O
as O
assessed O
by O
the O
patient's O
general O
status O
( O
e.g O
. O
cardiovascular O
status O
, O
pre-existing O
anaemia B-PHE
at O
the O
start O
of O
chemotherapy O
) O
. O

Also O
for O
used O
to O
increase O
the O
yield O
of O
autologous B-PHE
blood I-PHE
from O
patients O
in O
a O
predonation O
program O
. O

When O
administered O
subcutaneously O
, O
Epoetin O
Zeta O
is O
equivalent O
to O
Epoetin O
Alfa O
in O
terms O
of O
clinical O
effectiveness O
. O

-DOCSTART- O


Neoplasms B-PHE
, I-PHE
Breast I-PHE

-DOCSTART- O


dissipate O
depression B-PHE

-DOCSTART- O


vomiting B-PHE
and O
diarrhea B-PHE
due O
to O
visceral O
cold B-PHE

-DOCSTART- O


Motivation O
, O
Mood O
, O
Physical B-PHE
performance B-PHE
and O
fitness B-PHE
, O
Endurance B-PHE
, O
energy O
supply O
and O
recovery B-PHE
, O
Others O
, O
effort O
, O
Mental B-PHE
state I-PHE
and I-PHE
performance I-PHE

-DOCSTART- O


Its O
active O
component O
, O
triterpenic O
acid O
, O
increases O
cornary O
flow O
and O
improve O
systemic B-PHE
circulation. I-PHE
. O

-DOCSTART- O


disperse O
cold B-PHE

-DOCSTART- O


epiphora B-PHE
; O
lacrimation B-PHE

-DOCSTART- O


Cardiovascular B-PHE
Disorder I-PHE

-DOCSTART- O


terminate O
delivery O

-DOCSTART- O


To O
supplement O
qi O
and O
nourish O
yin O
, O
clear O
fire O
and O
engender O
liquid O
. O

-DOCSTART- O


To O
dispel O
wind-heat B-PHE
, O
to O
promote O
eruption B-PHE
, O
and O
to O
cause O
diuresis B-PHE
. O

-DOCSTART- O


To O
resolve O
phlegm B-PHE
and O
benefit O
throat B-PHE

-DOCSTART- O


1 O
Aloperine O
inhibits O
exudative B-PHE
inflammation I-PHE
and O
hemolysis B-PHE
of O
red O
blood B-PHE
cells O
2 O
. O

Its O
decoction O
or O
sophocarpine O
relieves O
asthma B-PHE
in O
guinea-pigs O
induced O
by O
acetylcholine O
and O
histamine O
. O

3 O
. O
Sophocarpine O
or O
matrine O
inhibits O
sarcoma180 B-PHE
in O
vitro O
. O

-DOCSTART- O


Shosaikoto O
, O
which O
is O
one O
of O
the O
Japanese O
and O
Chinese O
traditional O
herbal O
medicine O
mixtures O
, O
has O
several O
immunomodulating B-PHE
activities I-PHE
. O

Especially O
, O
Shosaikoto O
is O
a O
potent O
polyclonal O
B O
cell O
mitogen O
in O
vivo O
and O
in O
vitro O
. O

In O
order O
to O
characterize O
the O
active O
substances O
for O
mitogenic B-PHE
activity I-PHE
, O
Shosaikoto O
was O
fractionated O
by O
means O
of O
ethanol O
precipitation O
to O
give O
two O
fractions O
, O
called O
ethanol-precipitate O
( O
EP O
) O
fraction O
and O
ethanol-soluble O
( O
ES O
) O
fraction O
. O

The O
EP O
fraction O
consisted O
mainly O
of O
polysaccharides O
and O
showed O
significant O
mitogenic B-PHE
activity I-PHE
. O

The O
ES O
fraction O
consisted O
of O
low O
molecular O
compounds O
and O
did O
not O
show O
the O
activity O
in O
vitro O
. O

The O
EP O
fraction O
of O
hot O
water O
extracts O
of O
Glycyrrhizae O
Radix O
and O
Bupureuri O
Radix O
showed O
the O
activities O
, O
and O
the O
ES O
fraction O
of O
a O
hot O
water O
extract O
of O
Glycyrrhizae O
Radix O
and O
all O
fractions O
of O
hot O
water O
extract O
of O
Scutellariae O
Radix O
showed O
the O
cytotoxicity O
. O

These O
results O
suggested O
that O
the O
crude O
polysaccharide O
fractions O
could O
play O
an O
important O
role O
in O
the O
mitogenic B-PHE
activity I-PHE
by O
Shosaikoto O
. O

-DOCSTART- O


Decompensated B-PHE
Cirrhosis I-PHE

-DOCSTART- O


Cough B-PHE
and O
asthma B-PHE
, O
fright O
epilepsy B-PHE
, O
wind-cold-damp B-PHE
impediment I-PHE
, O
dysentery B-PHE
, O
prolapse B-PHE
of I-PHE
rectum I-PHE
, O
knocks B-PHE
and O
falls B-PHE
. O

-DOCSTART- O


Cardiovascular B-PHE
Diseases I-PHE

-DOCSTART- O


1 O
Its O
decoction O
enhances O
th O
intestinal B-PHE
contraction I-PHE
and O
tensity O
of O
rabbits O
in O
vitro O
, O
which O
can O
be O
counteracted O
by O
atropine O
. O

2 O
. O
Inhibiting O
the O
growth O
of O
sarcoma B-PHE
180 I-PHE
in O
mice O
. O

-DOCSTART- O


1 O
To O
clear O
heat B-PHE
and O
toxic B-PHE
material I-PHE
, O
deprive O
dampness B-PHE
and O
kill O
parasites B-PHE
. O

For O
sorethroat B-PHE
, O
dysentery B-PHE
, O
trichomonas B-PHE
enteritis I-PHE
, O
toothache B-PHE
, O
stomachache B-PHE
and O
leucorrhagia B-PHE
, O
external O
use O
for O
tinea B-PHE
and O
eczema B-PHE
. O

2 O
To O
relieve O
dyspnea B-PHE
and O
cough B-PHE
. O

3 O
Anticarcinogenic B-PHE
. O
For O
malignant B-PHE
hydatidiform I-PHE
mole I-PHE
, O
chorionic B-PHE
epithelioma I-PHE
and O
leukemia B-PHE
. O

-DOCSTART- O


Knee B-PHE
Osteoarthritis I-PHE

-DOCSTART- O


Malignancy B-PHE

-DOCSTART- O


Lysophospholipids O
have O
been O
found O
to O
mediate O
the O
activity O
of O
this O
drug O
. O

-DOCSTART- O


Crohn's B-PHE
Disease I-PHE

-DOCSTART- O


Swelling B-PHE
and O
pain B-PHE
due O
to O
blood B-PHE
stagnation I-PHE
caused O
by O
external B-PHE
injuries I-PHE
. O

-DOCSTART- O


Insulin O
binds O
to O
the O
insulin O
receptor O
( O
IR O
) O
, O
a O
heterotetrameric O
protein O
consisting O
of O
two O
extracellular O
alpha O
units O
and O
two O
transmembrane O
beta O
units O
. O

The O
binding O
of O
insulin O
to O
the O
alpha O
subunit O
of O
IR O
stimulates O
the O
tyrosine B-PHE
kinase I-PHE
activity O
intrinsic O
to O
the O
beta O
subunit O
of O
the O
receptor O
. O

The O
bound O
receptor O
is O
able O
to O
autophosphorylate O
and O
phosphorylate O
numerous O
intracellular O
substrates O
such O
as O
insulin O
receptor O
substrates O
( O
IRS O
) O
proteins O
, O
Cbl B-PHE
, O
APS B-PHE
, O
Shc B-PHE
and O
Gab B-PHE

These O
activated O
proteins O
, O
in O
turn O
, O
lead O
to O
the O
activation B-PHE
of I-PHE
downstream I-PHE
signaling I-PHE
molecules I-PHE
including O
PI3 B-PHE
kinase I-PHE
and O
Akt B-PHE
. O

Akt O
regulates O
the O
activity B-PHE
of I-PHE
glucose I-PHE
transporter I-PHE
4 I-PHE
( O
GLUT4 B-PHE
) O
and O
protein B-PHE
kinase I-PHE
C I-PHE
( O
PKC B-PHE
) O
which O
play O
a O
critical O
role O
in O
metabolism O
. O

-DOCSTART- O


Treatment O
of O
rheumatic B-PHE
arthritis I-PHE
with O
muscular B-PHE
contracture I-PHE
, O
aching B-PHE
of O
the O
loins O
and O
knees O
, O
inflammation B-PHE
of O
the O
throat O
, O
carbuncle B-PHE
and O
boils O
, O
traumatic B-PHE
injuries I-PHE
. O

-DOCSTART- O


Imatinib O
binds O
to O
an O
intracellular O
pocket O
located O
within O
tyrosine B-PHE
kinases I-PHE
( O
TK B-PHE
) O
, O
thereby O
inhibiting O
ATP B-PHE
binding I-PHE
and O
preventing O
phosphorylation B-PHE
and O
the O
subsequent O
activation O
of O
growth O
receptors O
and O
their O
downstream O
signal B-PHE
transduction I-PHE
pathways I-PHE
. O

Temozolomide O
is O
converted O
at O
physiologic O
pH O
to O
the O
short-lived O
active O
compound O
, O
monomethyl O
triazeno O
imidazole O
carboxamide O
( O
MTIC O
) O
. O

The O
cytotoxicity B-PHE
of I-PHE
MTIC I-PHE
is O
due O
primarily O
to O
methylation B-PHE
of I-PHE
DNA I-PHE
at O
the O
O6 O
and O
N7 O
positions O
of O
guanine O
, O
resulting O
in O
inhibition B-PHE
of I-PHE
DNA I-PHE
replication I-PHE
. O

-DOCSTART- O


Growth B-PHE

-DOCSTART- O


Treatment O
of O
: O
1 O
Hemorrhages B-PHE
due O
to O
external B-PHE
injuries I-PHE
. O
Dragon's O
blood O
( O
Xuejie O
) O
can O
be O
taken O
alone O
for O
external O
use O
, O
or O
it O
can O
be O
combined O
with O
Cattail O
pollen O
( O
Puhuang O
) O
. O

-DOCSTART- O


A O
74-year-old O
man O
was O
admitted O
to O
our O
hospital O
complaining O
of O
severe O
neck B-PHE
pain I-PHE
and O
general O
fatigue B-PHE
. O

He O
had O
been O
undergoing O
treatment O
for O
post-operative O
neck B-PHE
pain I-PHE
at O
the O
out-patient O
clinic O
of O
our O
hospital O
, O
but O
was O
now O
complaining O
of O
pain B-PHE
more O
intense O
than O
usual O
. O

Chest O
X-rays O
revealed O
diffuse O
ground O
glass O
shadows O
in O
bilateral O
lung O
fields O
, O
and O
computed O
tomography O
revealed O
diffuse O
intestinal O
shadows O
. O

A O
drug O
lymphocyte O
stimulation O
test O
( O
DLST O
) O
was O
also O
performed O
at O
that O
time O
. O

Steroid O
pulse O
therapy O
improved O
the O
clinical O
symptoms O
, O
hypoxemia B-PHE
and O
chest O
X-ray O
findings O
. O

DLST O
performed O
again O
with O
Yokukansan O
and O
Hachimijiogan O
133 O
days O
after O
the O
initial O
diagnosis O
of O
pneumonitis O
showed O
Yokukansan O
was O
positive O
. O

This O
result O
showed O
Yukukansan O
may O
be O
a O
causative O
drug O
for O
allergic O
drug-induced B-PHE
pneumonitis I-PHE
. O

Any O
drugs O
including O
kanpo O
may O
be O
possible O
to O
induce O
allergic B-PHE
pneumonitis I-PHE
. O

-DOCSTART- O


insulin B-PHE
sensitivity I-PHE
and O
diabetes B-PHE
risk I-PHE
, O
Body B-PHE
weight I-PHE
regulation I-PHE
, O
Improvement O
of O
blood B-PHE
glucose I-PHE
levels I-PHE
, O
Hemostatic B-PHE
function I-PHE
, O
Diet B-PHE
related I-PHE
cardiovascular I-PHE
disease I-PHE

-DOCSTART- O


Alzheimer B-PHE
Disease I-PHE

-DOCSTART- O


To O
dispel O
wind-heat B-PHE
, O
to O
subdue O
hyperactivity B-PHE
of I-PHE
the I-PHE
liver I-PHE
, O
and O
improve O
eyesight B-PHE
. O

-DOCSTART- O


Investigated O
for O
use/treatment O
in O
depression B-PHE
. O

-DOCSTART- O


To O
stop O
bleeding B-PHE
and O
promote O
the O
healing B-PHE
of I-PHE
wounds I-PHE
. O

-DOCSTART- O


seven O
injuries B-PHE
; O
seven O
kinds O
of O
impairments B-PHE

-DOCSTART- O


Regulation O
of O
qi O

-DOCSTART- O


Eye B-PHE
pain I-PHE
, O
eye B-PHE
swelling I-PHE
, O
red B-PHE
eyes I-PHE
and O
tearing B-PHE
. O

-DOCSTART- O


Its O
leaf O
infusion O
from O
NaCl O
solution O
inhibits O
the O
growth O
of O
Bacillus B-PHE
coli I-PHE
. O

-DOCSTART- O


phthisical B-PHE
cough I-PHE
due O
to O
Eum O
deficiency O

-DOCSTART- O


swollen O
check O
, O
mumps B-PHE
; O
epidemic B-PHE
parotitis I-PHE

-DOCSTART- O


Infection B-PHE

-DOCSTART- O


Behavioral B-PHE
and I-PHE
psychological I-PHE
symptoms I-PHE
of I-PHE
dementia I-PHE
( O
BPSD B-PHE
) O
are O
commonly O
seen O
in O
patients O
with O
Alzheimer's B-PHE
disease I-PHE
( O
AD B-PHE
) O
and O
other O
forms O
of O
senile B-PHE
dementia I-PHE
. O

BPSD B-PHE
have O
a O
serious O
impact O
on O
the O
quality O
of O
life O
of O
dementia B-PHE
patients O
, O
as O
well O
as O
their O
caregivers O
. O

However O
, O
an O
effective O
drug O
therapy O
for O
BPSD B-PHE
has O
not O
been O
established O
. O

Recently O
, O
the O
traditional O
Japanese O
medicine O
Yokukansan O
( O
YKS O
, O
Yi-gan O
san O
in O
Chinese O
) O
has O
been O
reported O
to O
improve O
BPSD B-PHE
in O
a O
randomized O
, O
single-blind O
, O
placebo-controlled O
study O
. O

Moreover O
, O
abnormalities B-PHE
of I-PHE
the I-PHE
serotonin I-PHE
( O
5-HT B-PHE
) O
system O
such O
as O
5-HT2A O
receptors O
have O
been O
reported O
to O
be O
associated O
with O
BPSD B-PHE
of O
AD B-PHE
patients O
. O

In O
the O
present O
study O
, O
we O
investigated O
the O
effect O
of O
YKS O
on O
head-twitch O
response O
induced O
by O
2,5-dimethoxy-4-iodoamphetamine O
( O
DOI O
, O
5 O
mg/kg O
, O
i.p O
. O
) O
in O
mice O
, O
a O
behavioral O
response O
that O
is O
mediated O
, O
in O
part O
, O
by O
5-HT2A O
receptors O
. O

Acute O
treatment O
with O
YKS O
( O
100 O
and O
300 O
mg/kg O
, O
p.o O
. O
) O
had O
no O
effect O
on O
the O
DOI-induced B-PHE
head-twitch I-PHE
response I-PHE
, O
whilst O
14 O
days O
repeated O
treatment O
with O
YKS O
( O
300 O
mg/kg O
, O
p.o O
. O
) O
significantly O
inhibited O
this O
response O
. O

Moreover O
, O
repeated O
treatment O
with O
YKS O
( O
300 O
mg/kg O
, O
p.o O
. O
) O
decreased O
expression O
of O
5-HT2A O
receptors O
in O
the O
prefrontal O
cortex O
, O
which O
is O
part O
of O
the O
circuitry O
mediating O
the O
head-twitch B-PHE
response I-PHE
. O

These O
findings O
suggest O
that O
the O
inhibition O
of O
DOI-induced B-PHE
head-twitch I-PHE
response O
by O
YKS O
may O
be O
mediated O
, O
in O
part O
, O
by O
altered O
expression O
of O
5-HT2A O
receptors O
in O
the O
prefrontal O
cortex O
, O
which O
suggests O
the O
involvement O
of O
the O
5-HT B-PHE
system I-PHE
in O
psychopharmacological O
effects O
of O
YKS O
. O

-DOCSTART- O


Obesity B-PHE

-DOCSTART- O


relieve O
pain B-PHE

-DOCSTART- O


To O
eliminate O
phlegm B-PHE
and O
relieve O
cough B-PHE
. O

For O
acute O
and O
chronic B-PHE
bronchitis I-PHE
. O

-DOCSTART- O


Non-Small B-PHE
Cell I-PHE
Lung I-PHE
Cancer I-PHE

-DOCSTART- O


To O
regulate O
the O
qi O
of O
the O
liver B-PHE
and O
stomach B-PHE
, O
and O
relieve O
pain B-PHE
. O

-DOCSTART- O


Bacterial B-PHE
infections I-PHE
of O
the O
ear O

-DOCSTART- O


Urinary B-PHE
Bladder I-PHE
, I-PHE
Neurogenic I-PHE

-DOCSTART- O


Retention B-PHE
of I-PHE
milk I-PHE
in O
babies O
, O
profuse O
sputum B-PHE
and O
infantile B-PHE
convulsions I-PHE
. O

-DOCSTART- O


To O
stablize O
liver B-PHE
and O
suppress O
dizziness B-PHE
; O
To O
soothe O
neck B-PHE
and O
wake-up O
brain B-PHE

-DOCSTART- O


burn B-PHE

-DOCSTART- O


Melanoma B-PHE

-DOCSTART- O


reddish B-PHE
turbid I-PHE
urine I-PHE

-DOCSTART- O


night B-PHE
sweat I-PHE
and O
nocturnal B-PHE
emission I-PHE

-DOCSTART- O


urinary B-PHE
incontinence I-PHE
; O
galacturia B-PHE
; O
stranguria B-PHE
with O
chyluria B-PHE
; O
stranguria B-PHE
marked O
by O
chyluria B-PHE

-DOCSTART- O


To O
dissipate O
stasis B-PHE
and O
quicken O
blood B-PHE
, O
relieve O
pain B-PHE
. O

-DOCSTART- O


replenish O
essence-marrow O

-DOCSTART- O


( O
1 O
) O
diarrhea B-PHE
( O
2 O
) O
diarrhea B-PHE
and O
urination B-PHE
( O
3 O
) O
diarrhea B-PHE
and O
dysentery B-PHE

-DOCSTART- O


A O
UPLC/Q-TOF-MS/MS O
method O
for O
analyzing O
the O
constituents O
in O
rat O
plasma O
after O
oral O
administration O
of O
Yin O
Chen O
Hao O
Tang O
( O
YCHT O
) O
, O
a O
traditional O
Chinese O
medical O
formula O
, O
has O
been O
established O
. O

The O
UPLC/MS O
fingerprints O
of O
the O
samples O
were O
established O
first O
in O
vitro O
and O
in O
vivo O
, O
with O
45 O
compounds O
in O
YCHT O
and O
21 O
compounds O
in O
rat O
plasma O
after O
oral O
administration O
of O
YCHT O
were O
detected O
. O

Of O
the O
45 O
detected O
compounds O
in O
vitro O
, O
30 O
were O
identified O
, O
and O
all O
of O
the O
21 O
compounds O
detected O
in O
rat O
plasma O
were O
identified O
either O
by O
comparing O
the O
retention O
time O
and O
mass O
spectrometry O
data O
with O
that O
of O
reference O
compounds O
or O
by O
mass O
spectrometry O
analysis O
and O
retrieving O
the O
reference O
literatures O
. O

Of O
the O
identified O
21 O
compounds O
in O
rat O
plasma O
, O
19 O
were O
the O
original O
form O
of O
compounds O
absorbed O
from O
the O
45 O
detected O
compounds O
in O
vitro O
, O
2 O
were O
the O
metabolites O
of O
the O
compounds O
existed O
in O
YCHT O
. O

It O
is O
concluded O
that O
a O
rapid O
and O
validated O
method O
has O
been O
developed O
based O
on O
UPLC-MS/MS O
, O
which O
shows O
high O
sensitivity O
and O
resolution O
that O
is O
more O
suitable O
for O
identifying O
the O
bioactive O
constituents O
in O
plasma O
after O
oral O
administration O
of O
Chinese O
herbal O
medicines O
, O
and O
provides O
helpful O
chemical O
information O
for O
further O
pharmacology O
and O
active O
mechanism O
research O
on O
the O
Chinese O
medical O
formula O
. O

-DOCSTART- O


Ureteral B-PHE
Stent I-PHE
Occlusion I-PHE

-DOCSTART- O


De O
Novo O
Kidney O
Transplant O
Patients O

-DOCSTART- O


Glaucoma B-PHE

-DOCSTART- O


excessive O
drinking O
of O
water O
due O
to O
thirst B-PHE

-DOCSTART- O


To O
dispel O
wind B-PHE
and O
eliminate O
damp B-PHE
, O
soothe O
sinews B-PHE
and O
free O
network O
vessels B-PHE
. O

-DOCSTART- O


Ovarian B-PHE
Hyperstimulation I-PHE
Syndrome I-PHE

-DOCSTART- O


Rosuvastatin O
is O
a O
competitive O
inhibitor O
of O
HMG-CoA O
reductase O
, O
which O
reductase O
catalyzes O
the O
conversion O
of O
HMG-CoA O
to O
mevalonate O
, O
an O
early O
rate-limiting O
step O
in O
cholesterol O
biosynthesis O
. O

Lapaquistat O
acetate O
is O
a O
squalene O
synthase O
inhibitor O
investigated O
for O
the O
treatment O
of O
hypercholesterolemia B-PHE
. O

-DOCSTART- O


moisten O
the O
liver B-PHE

-DOCSTART- O


vomiting B-PHE
of O
milk O

-DOCSTART- O


Oxcarbazepine O
produces O
blockade B-PHE
of I-PHE
voltage-sensitive I-PHE
sodium I-PHE
channels I-PHE
, O
resulting O
in O
stabilization O
of O
hyperexcited O
neural B-PHE
membranes I-PHE
, O
inhibition O
of O
repetitive B-PHE
neuronal I-PHE
firing I-PHE
, O
and O
diminution O
of O
propagation B-PHE
of I-PHE
synaptic I-PHE
impulses I-PHE
. O

These O
actions O
are O
thought O
to O
be O
important O
in O
the O
prevention O
of O
seizure B-PHE
spread I-PHE
in O
the O
intact O
brain O
. O

Gabapentin's O
therapeutic O
action O
on O
neuropathic B-PHE
pain I-PHE
is O
thought O
to O
involve O
voltage-gated B-PHE
N-type I-PHE
calcium I-PHE
ion I-PHE
channels I-PHE
. O

It O
is O
thought O
to O
bind O
to O
the O
subunit O
(1 O
and O
2) O
of O
the O
voltage-dependent B-PHE
calcium I-PHE
channel I-PHE
in O
the O
central O
nervous O
system O
. O

-DOCSTART- O


Toxoplasmosis B-PHE

-DOCSTART- O


white B-PHE
turbid I-PHE
urine I-PHE

-DOCSTART- O


nourish O
essence-marrow B-PHE

-DOCSTART- O


Childhood B-PHE
Acute I-PHE
Myelomonocytic I-PHE
Leukemia I-PHE

-DOCSTART- O


warm O
the O
menses B-PHE
and O
stop O
bleeding B-PHE

-DOCSTART- O


To O
dispel O
wind B-PHE
, O
resolve O
phlegm B-PHE
and O
promote O
blood B-PHE
circulation I-PHE
to O
remove O
obstruction B-PHE
in I-PHE
the I-PHE
channels I-PHE
. O

-DOCSTART- O


Atrophic B-PHE
Vaginitis I-PHE

-DOCSTART- O


Treatment O
of O
stagnation B-PHE
of I-PHE
undigested I-PHE
meat I-PHE
with O
epigastric B-PHE
distension I-PHE
, O
diarrhea B-PHE
and O
abdominal B-PHE
pain I-PHE
, O
amenorrhea B-PHE
due O
to O
blood B-PHE
stasis I-PHE
, O
epigastric B-PHE
pain I-PHE
or O
abdominal B-PHE
colic I-PHE
, O
after O
childbirth O
, O
heraial O
pain B-PHE
, O
hyperlipemia B-PHE
. O

-DOCSTART- O


cough B-PHE
due O
to O
dryness B-PHE
of I-PHE
the I-PHE
lung I-PHE

-DOCSTART- O


profuse B-PHE
bleeding I-PHE
after O
delivery B-PHE

-DOCSTART- O


Adult B-PHE
Acute I-PHE
Myeloid I-PHE
Leukemia I-PHE
With O
Inv(16)(p13.1q22 O
) O
; O
CBFB-MYH11 O

-DOCSTART- O


secure O
the O
essence O

-DOCSTART- O


Septic B-PHE
Shock I-PHE

-DOCSTART- O


Sore B-PHE
Throat I-PHE
Due O
to O
a O
Common O
Cold B-PHE

-DOCSTART- O


Neuropathic B-PHE
pain I-PHE

-DOCSTART- O


cool O
blood B-PHE
and O
alleviate O
edema B-PHE

-DOCSTART- O


close O
sores B-PHE

-DOCSTART- O


Kids O
, O
Protective B-PHE
immunity I-PHE
, O
Metabolism B-PHE

-DOCSTART- O


